



Mistry, Shailesh N. and Valant, Celine and Sexton, Patrick M. and Capuano, Ben and Christopoulos, Arthur and Scammells, Peter J. (2013) Synthesis and pharmacological profiling of analogues of benzyl quinolone carboxylic acid (BQCA) as allosteric modulators of the M1 muscarinic receptor. *Journal of Medicinal Chemistry*, 56 (12). pp. 5151-5172. ISSN 0022-2623

Access from the University of Nottingham repository:

<http://eprints.nottingham.ac.uk/30413/1/jm-2013-00540b.R1%20-%20JMC%2056%2812%29%202013%205151.pdf>

Copyright and reuse:

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

- Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners.
- To the extent reasonable and practicable the material made available in Nottingham ePrints has been checked for eligibility before being made available.
- Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.
- Quotations or similar reproductions must be sufficiently acknowledged.

Please see our full end user licence at:

http://eprints.nottingham.ac.uk/end_user_agreement.pdf

A note on versions:

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please

see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact eprints@nottingham.ac.uk

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

**Synthesis and Pharmacological Profiling of Analogues of
Benzyl Quinolone Carboxylic Acid (BQCA) as Allosteric
Modulators of the M1 Muscarinic Receptor**

Journal:	<i>Journal of Medicinal Chemistry</i>
Manuscript ID:	jm-2013-00540b.R1
Manuscript Type:	Article
Date Submitted by the Author:	14-May-2013
Complete List of Authors:	Mistry, Shailesh; Monash University, Medicinal Chemistry Valant, Celine; Monash University, Pharmacology Sexton, Patrick; Monash University, Department of Pharmacology Capuano, Ben; Monash University, Department of Medicinal Chemistry, Victorian College of Pharmacy Christopoulos, Arthur; Monash Institute of Pharmaceutical Sciences, Drug Discovery Biology Scammells, Peter; Monash University, Medicinal Chemistry

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 **Synthesis and Pharmacological Profiling of Analogues of**
7
8
9 **Benzyl Quinolone Carboxylic Acid (BQCA) as Allosteric**
10
11
12 **Modulators of the M₁ Muscarinic Receptor**
13
14
15
16
17
18
19

20 Shailesh N. Mistry,^{†,§} Celine Valant,^{‡,§} Patrick M. Sexton,[‡] Ben Capuano,[†] Arthur
21
22
23 Christopoulos^{‡,*} and Peter J. Scammells^{†,*}
24
25
26
27
28
29

30 [†]Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville,
31
32 Victoria, 3052, Australia.
33
34

35 [‡]Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University,
36
37 Parkville, Victoria, 3052, Australia.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Established therapy in Alzheimer's disease involves potentiation of the endogenous orthosteric ligand, acetylcholine, at the M₁ muscarinic receptors found in higher concentrations in the cortex and hippocampus. Adverse effects, due to indiscriminate activation of other muscarinic receptor subtypes, are common. M₁ muscarinic positive allosteric modulators/allosteric agonists such as BQCA offer an attractive solution, being exquisitely M₁-selective over other muscarinic subtypes.

A common difficulty with allosteric ligands is interpreting SAR, based on composite potency values derived in the presence of fixed concentration of agonist. In reality these values encompass multiple pharmacological parameters – each potentially, and differentially sensitive to structural modification of the ligand.

We report novel BQCA analogues which appear to augment ligand affinity for the receptor (pK_B), intrinsic efficacy (τ_B) and both binding (α) and functional (β) cooperativity with acetylcholine. Ultimately, development of such enriched SAR surrounding allosteric modulators will provide insight into their mode of action.

INTRODUCTION

Alzheimer's disease is a progressively debilitating, neurodegenerative disorder, primarily affecting the ageing population. Though first described over 100 years ago, the underlying causative factors are yet to be identified. Symptoms include confusion, memory loss and dementia, ultimately leading to death. Progressive degeneration of cholinergic neurons in several brain areas, including the cerebral cortex and hippocampus, is known to occur. In particular, the muscarinic M₁ receptor has been found to be more prevalent in these same areas of the brain.^{1,2}

Although no disease modifying therapy is currently available, the majority of pharmacotherapy provides symptomatic relief through augmentation of cholinergic function, via administration of anticholinesterase inhibitors. The undesired effects (e.g. nausea, vomiting, bradycardia) of this type of therapy result from indiscriminate augmentation of the endogenous orthosteric ligand; acetylcholine (ACh), and subsequent non-selective overactivation of other muscarinic receptor subtypes (M₂-M₅).³ A selective orthosteric agonist of the M₁ receptor is likely to offer better therapy, through fewer off-target effects. However, subtype selectivity within the muscarinic receptors is notoriously difficult to achieve, primarily due to the highly conserved amino acid sequence within the orthosteric site of each muscarinic receptor subtype.⁴

More recently, compounds binding to topographically distinct sites on the receptor (allosteric sites), able to potentiate the agonist activity of an orthosteric ligand (positive allosteric modulators, PAMs), or activate the receptor in their own right as well as potentiating agonist activity (allosteric agonists), have been discovered.⁵ PAMs have the potential to offer a more desirable therapeutic profile than classic orthosteric agonists, as they would potentiate endogenous ligand activity (via altering affinity, efficacy, or both) under more physiological conditions, rather than the unselective and continuous agonist activity conferred by an orthosteric agonist. In addition, the potential for subtype selectivity is higher, due to less evolutionary pressure to conserve amino acid sequences that are not within the orthosteric site.⁵

1
2
3 The compound 1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (BQCA), has
4
5 been shown to exhibit unprecedented positive allosteric activity for ACh binding as well as inherent
6
7 agonist activity at the M₁ muscarinic receptor.^{6,7} Additionally, BQCA appears to display high
8
9 subtype selectivity, with no activity detected at concentrations up to 100 μM at any of the other four
10
11 muscarinic receptor subtypes, in several assays.^{6,8}

12
13
14 Among the previously reported structure-activity relationships (SARs), one study especially
15
16 suggests that the activity of BQCA analogues as M₁ muscarinic PAMs is improved by incorporation
17
18 of fluorine atoms at either or both the 5- and 8-positions of the quinolone ring.⁹ However, all of
19
20 these SAR studies are based on an ‘allosteric potency’ value, determined from titration of the
21
22 modulator in the presence of a fixed (e.g., EC₂₀) concentration of the endogenous ligand, ACh. The
23
24 main issue with such titration curves is that the estimated ‘allosteric potency’ reflects a composite
25
26 of at least four operational properties,¹⁰ namely; the affinity of the modulator for the free receptor
27
28 (K_B), its allosteric effects on the binding and signalling of the orthosteric ligand (α and β ,
29
30 respectively), and its intrinsic agonist efficacy (if any) in the system (τ_B). In reality, each of these
31
32 parameters may be separately “tuned” through chemical modification, often in opposite directions
33
34 such that minimal changes may be observed in the composite allosteric potency parameter.
35
36 Consequently, use of an all-encompassing allosteric potency value can lead to misinterpretation of
37
38 SAR data. In fact, a common observation in the field, based predominantly on this approach, is that
39
40 allosteric ligand SAR is often “flat”.^{5,11}

41
42
43
44
45 Our approach to allosteric ligand SAR is based on the premise that a more thorough profiling of
46
47 key-selected compounds would allow us to correlate chemical modifications to each of the
48
49 individual operational parameters of the modulator (affinity, binding/functional cooperativity and
50
51 efficacy). Therefore, using an operational model of allosterism that we have previously described,
52
53^{7,10} we sought to quantify the effect of subtle chemical changes on each of the four pharmacological
54
55 parameters, generating an ‘enriched allosteric ligands SAR’ study.
56
57
58
59
60

1
2
3 With this in mind, we have synthesised over 35 novel compounds based on the BQCA scaffold
4 and introduced four key structural modifications, namely; alternative substitution of the quinolone
5 ring in the 5- and 8-positions, isosteric replacement of the carboxylic acid moiety or amide
6 derivatives of the acid function and finally, replacement of the N-alkyl group. We characterised
7 each of these compounds in radioligand binding experiments to provide affinity and binding
8 cooperativity estimates, then investigated the agonist properties of ten of the most effective
9 modulators by quantifying their efficacy in an intracellular calcium-mobilization assay. Finally,
10 using the same functional assay, we assessed five of the most relevant allosteric agonist analogues
11 of BQCA in full interaction studies with ACh to provide functional allosteric modulation estimates.
12 With this approach we have been able to better define the key moieties triggering the affinity,
13 cooperativity and efficacy of BQCA and its analogues for the M₁ muscarinic receptor, in addition to
14 gathering some information about the nature of the allosteric binding pocket implicated. By
15 generating such enriched allosteric SAR, we believe it is possible to rationally design allosteric
16 ligands for GPCRs with tailored characteristics (affinity, cooperativity or agonism). In addition,
17 such SAR provides valuable insight into the nature of the target allosteric binding site.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS AND DISCUSSION

Chemistry. The 4-oxo-1,4-dihydroquinoline moiety is prevalent in a variety of reported compounds, thus its synthesis is well established. Rapid access to series of analogues substituted at the 5- and 8-positions of the 4-oxo-1,4-dihydroquinoline ring system was achieved using the appropriately substituted aniline as a starting material, utilising Gould-Jacobs chemistry.¹² Two parallel sets of compounds were easily obtained by variation of the alkyl halide at the N-alkylation step, using literature precedent to determine the choice of electrophile.⁹

Initial thermal condensation of a variety of 2- or 2,5-disubstituted anilines with commercially available diethylethoxymethylene malonate gave substituted (phenylamino)methylene malonates **1a-d** in good yield (Scheme 1). Compounds generally solidified from the neat reaction mixture on cooling. Subsequent cyclisation of **1a-d** to quinolones **2a-d** was carried out with varied yield, by heating in the presence of Eaton's reagent (1:10 w/w P₂O₅ in methanesulfonic acid). Typically this type of cyclisation has been achieved using diphenyl ether as the solvent, requiring high temperatures (over 200 °C).^{9,13} In addition, diphenyl ether can prove difficult to remove when used as a solvent, becoming a viscous liquid or solid on cooling. In comparison, Eaton's reagent¹⁴ offers lower temperatures, easy removal (being water miscible) and higher yields.¹⁵ Subsequent selective N-alkylation proceeded in generally good yield, with crude product precipitating from the reaction mixture after addition of water to afford the ester precursors **3a-d** and **4a-d**. Finally the desired free acids **5a-d** and **6a-d** were obtained after either acidic or basic hydrolysis under standard conditions. It was found more aggressive basic hydrolysis of ester **4a** resulted in displacement of the 5-F group, presumably *via* a S_NAr mechanism, to give phenolic compound **7**.

<insert Scheme 1 here>

Amide derivatives of 5,8-difluoro BQCA were obtained through several synthetic routes, starting with either carboxylic acid **5a** (Scheme 2) or the corresponding ethyl ester **3a** (Scheme 3). Although

1
2
3 several amides (**8a**, **8c**, **8d**, **8g-h**) were obtained after condensation of the appropriate amine with
4
5 the corresponding acid chloride derivative of **5a** (not isolated), this method gave generally poor
6
7 yields with several side products. In addition, some N-debenzylation was observed, presumably
8
9 during conversion to the acid chloride, under Vilsmeier-Haack conditions. With the aim of
10
11 improving yields and using milder conditions, the coupling reagent HCTU was employed, with
12
13 DIPEA as a base. This afforded amides (**8b**, **8e**, **8f**) in good to excellent yield, with negligible side
14
15 product formation.
16
17
18
19
20

21 <insert Scheme 2 here>
22
23
24

25 In the case of amides **10a-b** and **11**, direct aminolysis of ester **3a** proved to be a viable option.
26
27 Stirring at room temperature in the presence of MeNH₂ (aq), ethanolamine or ammonium hydroxide
28
29 respectively gave the desired products in excellent yields (Scheme 3).
30
31
32

33 <insert Scheme 3 here>
34
35
36
37

38 Compounds bearing established acid isosteric groups were easily accessible *via* common
39
40 intermediates employed in the synthesis of amide derivatives described above. Condensation of the
41
42 acid chloride intermediate (Scheme 2) with hydroxylamine, gave the corresponding hydroxamic
43
44 acid **8i**, whilst using methanesulfonamide in the presence of TEA, gave acylsulfonamide **9**,
45
46 following previously reported conditions.¹⁶
47
48

49 Carboxamide **11** was a useful precursor to both the tetrazole **13** and imide **14** (Scheme 3). Initial
50
51 dehydration of **11** in the presence of PdCl₂ in MeCN,¹⁷ gave the corresponding nitrile **12**. This was
52
53 cyclised with NaN₃ to form tetrazole **13** using reported methodology.¹⁸ Acylation of **11** was readily
54
55 achieved with Ac₂O/pyridine to give imide **14**.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

<insert Scheme 4 here>

Although compounds bearing different N-alkyl groups could be readily accessed through direct N-alkylation of intermediate **2a**, as before (Scheme 4); there were several target compounds that were not accessible through this route. Construction of the 4-oxo-dihydroquinoline core *via* a tandem addition-elimination mechanism, where a substituted amine nucleophile ultimately forms part of the bicyclic core has also been widely reported,^{9,19} and was employed to synthesise derivatives **26a-b**, **28**, **29**, **31** and **32** (Scheme 5).

To interrogate the environment surrounding the substituted *N*-benzyl group, positional isomers of the literature compound **6a**, bearing phenyl substituents in the 2- and 3- position of the benzyl pendant were synthesised (**16a** and **16b**, respectively) (Scheme 4). These were readily accessed in the same manner as the corresponding 4-phenylbenzyl compound **6a**. An additional analogue, bearing the 4-(3-aminopropynyl)benzyl group was also made, as this allowed probing of the 4'-position further incorporating both a linear extension to the ring and a polar, charged head group.

Initial *N*-Boc protection of propargyl amine proceeded in excellent yield using mild aqueous conditions to give carbamate **18**. Subsequent Sonogashira coupling²⁰ in the presence of CuI and PdCl₂(PPh₃)₂ afforded the arylalkynyl conjugate **19**. The benzylic alcohol group was converted to the corresponding benzylic bromide **20** in moderate yield, using standard Appel²¹ conditions. Compound **20** was then used to alkylate ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (**2a**) as previously described, giving compound **21**. Under aqueous acidic conditions, with heating, ester hydrolysis and *N*-Boc cleavage of **21** occurred in one step, affording amino acid **22** as the hydrochloride salt.

Although similar compounds are present in the quinolone class of antibiotic therapeutics, to our knowledge, there are no reported examples of the *N*-aryl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid class possessing allosteric activity at the M₁ muscarinic receptor. These compounds were of

1
2
3 interest as they differ from the core BQCA-type structure, only by the absence of the methylene
4
5 group linking the two aromatic moieties. To assess whether such a structure would be viable as an
6
7 M_1 allosteric modulator, compounds **26a** and **26b** were synthesised (Scheme 5).
8
9

10
11
12 <insert Scheme 5 here>
13
14
15

16 The final group of compounds of interest incorporated a piperidin-4-ylmethyl group in
17 replacement of the pendant substituted benzyl group (Scheme 5, compounds **28**, **29**, **30**, **31**).
18
19 Although similar structures have been incorporated into M_1 muscarinic allosteric compounds of the
20 quinolizidinone class,^{5,22-24} to our knowledge, no such moieties have been reported attached to the
21
22 4-oxo-1,4-dihydroquinoline-3-carboxylic acid core.
23
24
25

26 27 **Pharmacology.**

28
29 According to a previous study utilizing modulator titration curves, the biological activity of
30 BQCA analogues as M_1 muscarinic PAMs of ACh activity in a calcium mobilisation assay, was
31 improved by incorporation of fluorine atoms at the 5- and/or 8-positions of the quinolone ring.⁹ In
32 order to elucidate the effect engendered by the presence of these electronegative atoms on the
33 BQCA scaffold, we decided to investigate the effects of the fluorine incorporation on each of the
34 four operational parameters describing allosteric modulation by comparing **5a** to BQCA (Figure 1,
35 Table 1). To assess the binding activity of **5a**, we initially performed radioligand binding
36 experiments, using M_1 -expressing CHO cells in the presence of a K_D concentration of the
37 radiolabelled antagonist [³H]-NMS (0.1 nM), increasing concentrations of ACh with or without
38 increasing concentrations of **5a**. Such binding interaction studies allowed us to estimate the affinity
39 (pK_B) of the modulator for the allosteric site of the M_1 muscarinic receptor, as well as its binding
40 cooperativity ($\log\alpha$) with the endogenous ligand, ACh. Compared to BQCA, the affinity estimate of
41
42 **5a** ($pK_B = 4.96 \pm 0.13$) was very similar to that of BQCA ($pK_B = 4.72 \pm 0.07$), and the binding
43 cooperativity exerted by **5a** on ACh binding ($\log\alpha = 2.68 \pm 0.16$; $\alpha = 420$) was also not significantly
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 different from that exerted by BQCA ($\log\alpha = 2.60 \pm 0.11$; $\alpha = 400$). Next, we investigated the
4
5 agonist properties of **5a** compared to BQCA, in a calcium mobilization assay. As expected, ACh
6
7 was a full agonist in the system, with a potency estimate in the nanomolar range ($pEC_{50} = 8.75 \pm$
8
9 0.12). Interestingly, both allosteric ligands were full (allosteric) agonists in the M_1 -expressing CHO
10
11 cells, albeit with lower potency compared to ACh; $pEC_{50} = 6.89 \pm 0.11$ and 7.50 ± 0.20 for BQCA
12
13 and **5a**, respectively. We estimated the efficacy of both modulators in the system. Interestingly, **5a**
14
15 appeared to have significantly greater efficacy ($\log\tau_B = 2.18 \pm 0.06$; $\tau_B = 150$) compared to BQCA
16
17 ($\log\tau_B = 1.45 \pm 0.09$; $\tau_B = 28$). Finally, we interacted either BQCA or **5a** with ACh in a calcium
18
19 mobilisation assay to estimate the composite cooperativity parameter on binding and function
20
21 ($\log\alpha\beta$) in this assay, using an operational model of allosteric agonism. Notably, both BQCA and
22
23 **5a**, exhibited comparable binding/function cooperativity estimates, with $\log\alpha\beta = 2.72 \pm 0.13$ ($\alpha\beta =$
24
25 525) and $\log\alpha\beta = 2.31 \pm 0.28$ ($\alpha\beta = 205$) for BQCA and **5a**, respectively. As mentioned previously,
26
27 the ‘allosteric potency’ estimated by generation of titration curves reflects a composite of affinity,
28
29 binding/functional cooperativity and efficacy. Therefore, taken together, these findings suggest that
30
31 the observed improved biological activity of **5a** compared to BQCA is predominantly driven by an
32
33 improvement in the agonist properties of the modulator (τ_B) rather than an improvement of its
34
35 affinity or allosteric properties (pK_B or α and β , respectively).
36
37
38
39
40
41
42

43 <insert Figure 1 here>
44
45
46

47 The next phase of this study aimed at investigating the effects of four key structural modifications
48
49 of the BQCA scaffold; alternative substitution of the quinolone ring in the 5- and 8- positions,
50
51 isosteric replacement of the carboxylic acid moiety or amide derivatives of the acid function and
52
53 finally the replacement of the *N*-alkyl group. Initially, radioligand binding experiments were carried
54
55 out for all ligands, as described above for BQCA and **5a**. This allowed us to determine both affinity
56
57 and binding cooperativity estimates for each of the modulators synthesised in this study. Further
58
59
60

1
2
3 functional characterisation in a Ca^{2+} mobilisation assay was carried out on selected analogues
4 exhibiting binding cooperativity with ACh (α) of more than 50-fold. Finally, a small selection of
5 allosteric agonist analogues of BQCA (where $\tau_B > 100$) were investigated further in order to
6 estimate the binding/functional cooperativity ($\log \alpha\beta$) of each analogue with ACh, thus allowing
7 estimates of functional cooperativity ($\log \beta$) to be extracted.
8
9

10
11
12
13
14 First, we investigated the importance of the 5- and 8-fluoro groups on the BQCA scaffold, with
15 compounds, **5b-d**, **6b-d** and **7**, as well as the previously reported **5a** and **6a**. The ester precursors
16 **3a-d** and **4a-d** were also incorporated in the study, to determine the role of the carboxylic acid
17 functionality. Interestingly, when comparing **5a** and the corresponding ester analogue **3a**, the
18 replacement of the carboxylic acid function by an ethyl ester group did not affect the affinity of the
19 analogue for the allosteric site, however had a dramatic effect on the binding cooperativity with
20 ACh, such that **3a** was virtually incapable of modulating ACh binding ($\log \alpha = 0.18 \pm 0.09$; $\alpha = 1.5$).
21 Additionally, replacement of the fluorine or hydrogen atoms with methoxy groups, in the ester-
22 modified analogues of BQCA (**3b-d**) did not show any improvement in binding cooperativity with
23 ACh. Similar results were obtained with the *N*-(4-phenyl)benzyl analogues (**4a-d**) with all four
24 analogues exhibiting similar affinity estimates to BQCA or **5a**, but considerably lower binding
25 cooperativity with ACh. In comparison, the corresponding 5- and 8- substituted carboxylic acid
26 derivatives (**5b-d**, **6b-d**) exhibited, a different profile of activity. With analogues retaining the *N*-(4-
27 methoxy)benzyl group (**5b-d**), no significant effect was observed on the analogues' affinity for the
28 M_1 muscarinic receptor. In contrast, the presence of an 8-OMe group was significantly detrimental
29 for the ligand's binding cooperativity with ACh (compare **5b-c** with **5a/5d** and **BQCA**), whereas a
30 5-OMe group (**5d**) had very little effect on the binding cooperativity estimate (compare **5d** to
31 **BQCA**).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53
54 Interestingly, replacement of the methoxy group in the R^3 position with a phenyl group (**6a-d**)
55 caused a significant increase in the affinity of each analogue for the allosteric site. Similarly to the
56 *N*-(4-methoxy)benzyl series (**5a-d**), the presence of an 8-OMe group (**6b-c**) was detrimental for the
57
58
59
60

1
2
3 ligand's binding cooperativity with ACh. As before, a 5-OMe group (**6d**) was better tolerated,
4
5 having less of an effect on the binding cooperativity estimate, compared to **6b** and **6c**.
6

7
8 Finally, replacement of the 5-F group of **6a** with a phenol moiety in compound **7** resulted in
9
10 around a 0.75 log unit drop in the binding cooperativity estimate, though still being comparable to
11
12 other compounds exhibiting high binding cooperativity estimates (**BQCA**, **5a**, **5d**).
13

14
15 These findings suggest that whilst the carboxylic acid functionality is not essential for ligand
16
17 affinity at the allosteric site (as masking with an ethyl ester group had no significant effect on pK_B),
18
19 it appears to be an important determinant of binding cooperativity with ACh. Additionally,
20
21 substitution to a methoxy group in the 8-position is detrimental for the binding cooperativity of the
22
23 ligand; while the same substituent at the 5-position causes relatively less reduction in binding
24
25 cooperativity. The 5-position is able to tolerate hydrogen bond donating (phenol), hydrogen bond
26
27 accepting (fluoro and methoxy) as well as non-hydrogen bonding groups (hydrogen atom). It may
28
29 be of importance to note that the phenolic group in **7** is ideally situated adjacent to the carbonyl
30
31 moiety in the 4-position, allowing a possible intramolecular hydrogen bond interaction to take
32
33 place. This may impact on the ability of the phenolic group to form other interactions (so may only
34
35 be functioning as a hydrogen bond acceptor).
36
37

38
39 According to the binding data, apart from **BQCA** and **5a**, the best modulators were **5d**, **6a**, **6d** and
40
41 **7**, with binding cooperativity (α) equal or higher than 50. We therefore investigated the agonist
42
43 properties of three of these analogues (**5d**, **6a** and **6d**).
44

45
46 All three modulators were full agonists, as observed for **5a**, in the calcium mobilisation assay.
47
48 Using an operational model of agonism, we derived estimates of the efficacy of each modulator (**5d**,
49
50 **6a** and **6d**), in the system. Interestingly, all three analogues exhibited significantly higher efficacy
51
52 estimates than **BQCA**. Incidentally, when comparing the three analogues to **5a**, both **6a** and **6d**
53
54 exhibited similar efficacy estimates, while **5d** was significantly lower than **5a**. These findings
55
56 suggest that modifications in the 5- and 8-positions of the **BQCA** scaffold consistently increase the
57
58 agonistic properties of the modulator, while having very little effect on their ability to modulate
59
60

1
2
3 ACh binding. Finally, only one analogue (**6a**) exhibited an efficacy estimate ($\log\tau_B = 2.37 \pm 0.20$;
4 $\tau_B = 240$) higher than 100. We therefore investigated the combined binding/functional cooperativity
5 of **6a** with ACh in a calcium mobilisation assay. Notably, the combined binding/function
6 cooperativity estimate of **6a**, was not significantly higher than that of BQCA or **5a**, with $\log\alpha\beta =$
7 2.87 ± 0.24 ($\alpha\beta = 740$). Overall, these findings suggest that modification at the 5- and 8-positions of
8 the BQCA scaffold increase the efficacy of the modulators in the system, whereas replacement of
9 the *N*-(4-methoxy)benzyl pendant with *N*-(4-phenyl)benzyl), increases the affinity of the modulator
10 for the allosteric site without affecting the binding cooperativity.
11
12
13
14
15
16
17
18
19

20 We then turned our attention to whether the carboxylic acid moiety of the 4-oxo-1,4-
21 dihydroquinoline-3-carboxylic acid core could be replaced by a group other than an ethyl ester. To
22 start, a series of novel amide derivatives, **8a-h**, **10a-b** and **11** were synthesised, incorporating
23 primary amides to bulky tertiary amides. The unsubstituted carboxamide **11** was found to retain
24 affinity, but lost an order of magnitude in binding cooperativity with ACh ($\log\alpha = 1.51 \pm 0.12$; $\alpha =$
25 32) relative to the parent acid **5a**. As mentioned previously, the corresponding ethyl ester **3a**
26 showed a complete loss of binding cooperativity with ACh, suggesting that the presence of
27 hydrogen bond donor functionality in R⁴ position may be of importance for binding cooperativity
28 with the endogenous ligand, rather than the size of the group. Supporting this hypothesis,
29 compounds **8d-f** and **10b**, which also possessed this hydrogen bond donor functionality, retained
30 appreciable binding cooperativity with ACh. Of particular interest is **8f** ($\log\alpha = 2.22 \pm 0.14$; $\alpha =$
31 170) that showed only a small drop in binding cooperativity relative to parent compound **5a**,
32 demonstrating that an acidic functionality is not essential for the transmission of cooperativity with
33 the endogenous ligand. The secondary alcohol group on this compound may be able to make further
34 interactions within the allosteric site. Interestingly, **10b**, which possessed a hydroxyethyl group and
35 should theoretically be able to make a similar type of interaction to **8f**, exhibited significantly lower
36 binding cooperativity with ACh ($\log\alpha = 0.96 \pm 0.12$; $\alpha = 9$) compared to **8f**. This suggests that the
37 cyclohexyl ring in **8f** is able to either make further desirable contacts with the receptor, or restrain
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the hydroxyl moiety in a manner that is energetically favourable, holding the compound in a more
4 desirable pose. Notably, the piperidyl analogue **8h** also retained appreciable binding cooperativity
5 with ACh, though lacks the amide proton. Conversely, methylamide **10a** and ethylamide **8a** lacked
6 appreciable positive binding cooperativity with ACh, suggesting that the presence of a simple
7 hydrogen bond moiety alone is not sufficient to explain the effect on binding cooperativity.
8
9

10
11 Further investigation of the importance of an acidic moiety at the 3-position of the 4-oxo-1,4-
12 dihydroquinoline ring was deemed possible through a series of carboxylic acid isosteres. Many of
13 these isosteres offer advantages in terms of ADMET properties, whilst also varying in strength of
14 acidity. Hydroxamic acid **8i** ($pK_a \sim 8-9$),²⁵ acylsulfonamide **9** ($pK_a \sim 4.5$),²⁶ tetrazole **13** ($pK_a \sim 5.4-$
15 7.2)²⁶ and imide **14** ($pK_a \sim 8-9$)²⁷ were synthesised and evaluated as they vary in both size and
16 acidity relative to the parent carboxylic acid **5a** ($pK_a \sim 6-7$)²⁸. In addition, the intermediate nitrile **12**
17 was screened, though not possessing any inherent acidic functionality. All of the acid isostere
18 analogues retained appreciable binding cooperativity with ACh ($\alpha > 10$). Consistently with what we
19 observed in the previous analogues, no significant effect on the analogues affinity estimates was
20 noted. Interestingly, the nitrile intermediate **12** suffered almost complete abolition of positive
21 binding cooperativity with ACh. When both acid isosteres and amide analogues are compared, it is
22 evident that replacement of carboxylic acid is tolerated at the level of the affinity parameter though
23 causes a reduction in binding cooperativity with ACh. The pK_a of the heteroatom-bonded hydrogen
24 does not appear to influence either the ability of binding or the binding cooperativity of the
25 modulators for the allosteric site. The possibility to make such replacements offers potential
26 improvements from a pharmacokinetic perspective, particularly in terms of intrinsic permeability
27 and CNS penetration (generally poor for BQCA-type analogues),^{8,9,29-31} especially with the
28 analogue **8f** that appears to retain satisfactory binding affinity and binding cooperativity.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 <insert Table 2 here>
57
58
59
60

1
2
3 According to the binding data, three analogues of **5a** exhibit binding cooperativity with ACh,
4 higher than 50. These three analogues, **8d**, **8f** and **13**, were therefore selected to investigate their
5 ability to induce agonist activity at the M₁ muscarinic receptor. We performed concentration-
6 response curves with all three analogues and estimated the efficacy parameter of each modulator.
7 Interestingly, compared to **5a**, the substitution of the carboxylic acid with either a benzylamide **8d**,
8 or a tetrazole **13**, had a deleterious effect on the efficacy of the modulator for the receptor with
9 $\log\tau_B = 1.25 \pm 0.20$; ($\tau_B = 18$) and $\log\tau_B = 0.99 \pm 0.07$; ($\tau_B = 10$) for **8d** and **13**, respectively.
10 Comparatively, the substitutions with a 2-hydroxycyclohexylamide, as in **8f**, had no significant
11 effect on the efficacy of the modulators; with efficacy estimates similar to the one observed for **5a**.
12 **8f** being the only analogue that exhibited good efficacy, we interacted this modulator with ACh in a
13 calcium-mobilization assay and observed that interestingly, **8f** exhibited a combined
14 binding/function cooperativity estimate slightly higher than **5a**, with $\log\alpha\beta = 2.92 \pm 0.06$ ($\alpha\beta =$
15 840). Thus far **8f** appears to be the only compound in this series that appears to exhibit appreciable
16 cooperativity through binding and function with ACh in the calcium mobilisation assay.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

<insert Table 3 here>

41 Probing of the *N*-alkyl pendant seemed prudent, given most of the related compounds reported,
42 focussed on a 4-substituted-benzyl group very early in the structural optimisation programme.<sup>9,22-
43 24,30-33</sup> Though compound **6a**, that exhibits over 1000-fold potentiation of ACh binding, has been
44 previously reported, to our knowledge, the related *N*-(2-phenyl)benzyl and *N*-(3-phenyl)benzyl
45 analogues are unreported. We synthesised the corresponding analogues **16a-b** and an additional
46 compound, **22** which probes the 4-position of the *N*-benzylic pendant in a more linear fashion *via* an
47 aminopropynyl group. Both **16a-b** had similar affinity relative to **6a**. In terms of binding
48 cooperativity, both compounds retain satisfactory cooperativity with ACh, albeit considerably less
49 than that observed with **6a**, such that over a log unit of cooperativity was lost with **16a** and **b**. The
50
51
52
53
54
55
56
57
58
59
60

1
2
3 amino compound **22** retained both affinity and exhibited only small reduction in binding
4 cooperativity relative to **5a** (to which it is structurally related). Overall, though the 4-position of the
5 *N*-benzylic pendant is still the favoured substitution, both the 2- and 3-phenyl substituted analogues
6 offer good affinity and appreciable binding cooperativity with ACh. The apparent ability to
7 exchange a variety of groups at the 4-position of the benzylic pendant, whilst retaining good
8 binding cooperativity with ACh, indicates the presence of a potentially open pocket within the
9 receptor. Compounds **16a** and **22** were selected to assess agonist properties. Both exhibited greater
10 than 50-fold binding cooperativity with ACh. In contrast, the 2-phenyl analogue **16a**, lost most of
11 its agonist properties compared to the 4-phenyl analogue **6a** ($\log\tau_B = 1.10 \pm 0.23$; $\tau_B = 13$).
12 Interestingly, the propargylamine derivative, **22**, exhibited just as good efficacy ($\log\tau_B = 2.29 \pm$
13 0.07 ; $\tau_B = 195$) as **5a**, its closest related analogue. Interacting **22**, the only compound with an
14 appreciable efficacy, with ACh in calcium mobilization assay provided a binding/function
15 cooperativity estimate nearly identical to the one established for **5a** ($\log\alpha\beta = 2.35 \pm 0.09$; $\alpha\beta = 225$).
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 <insert Table 4 here>
37
38
39

40 Finally, to further interrogate the *N*-substituent of the 4-oxo-1,4-dihydroquinoline core,
41 compounds removing the methylene linker to the pendant aromatic ring (**26a-b**) and those replacing
42 the aromatic ring with an aliphatic heterocycle were synthesized (**28**, **29**, **31** and **32**). Simple
43 removal of the methylene linker in **26a-b** completely abolished the ability of the analogues to
44 transmit cooperativity with ACh, when compared to BQCA. Similarly, all piperidyl-linked
45 compounds (**28**, **29**, **31** and **32**), which lack aromaticity, exhibited a heavy reduction in binding
46 cooperativity with ACh, relative to BQCA. In the case of amine salt **29** and *N*-benzyl amine **31**,
47 cooperative binding was completely abolished. However, the bulky urea **32** displayed some
48 remaining binding cooperativity with ACh, compared to **29** and **31**, suggesting that the loss of
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 cooperativity with ACh would rather be due to the potential protonation of the amine rather than the
4
5 introduction of a bulky group, though a more extensive set of analogues would need to be
6
7 investigated to establish this hypothesis. Taken together, the *N*-alkyl and *N*-aryl series suggest the
8
9 presence of a fairly open pocket removed from the core 4-oxo-1,4-dihydroquinoline structure,
10
11 which is able to tolerate a variety of groups differing in size and polarity. It would appear however,
12
13 that access to this proposed pocket is *via* a conformationally sensitive linker region, preferring
14
15 planar aromatic groups, hinged through a methylene unit. Indeed, literature would suggest that
16
17 branching or extension of the methylene linker is not tolerated.⁹ Taken with our findings that
18
19 removal of the linker is not tolerated in terms of retaining binding cooperativity, the methylene
20
21 linker appears thus far to be optimal.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CONCLUSIONS

The pharmacological activity of the prototypical selective M₁-Muscarinic PAM/allosteric agonist BQCA and related compounds, has only previously been described through an all-encompassing ‘allosteric potency’ estimate. In reality this estimate is comprised at least four operational parameters (K_B - affinity for the receptor; α and β - binding and functional cooperativity factors with the orthosteric ligand, respectively; and τ_B – intrinsic efficacy). With each of these parameters being independently tuneable through chemical modification, we first sought to define a robust pharmacological profile of BQCA and key related literature compounds **5a** and **6a**. Building on this, we initiated a SAR campaign, synthesising over 35 novel compounds with structural modification in four areas: alternative substitution of the 5- and 8- positions of the quinolone ring, isosteric replacement of the carboxylic acid moiety or amide derivatives and replacement of the pendant *N*-alkyl group.

Evaluation of the literature compounds BQCA, **5a** and **6a** revealed the mechanism through which 5,8-difluoro analogues display improved biological activity. This was found to be due to an increased intrinsic efficacy (τ_B), relative to BQCA. Related analogues bearing varied 5- and 8- substituents (**3a-d**, **4a-d**, **5a-d**, **6a-d** and **7**) on both the carboxylic acid and ester scaffold revealed that though the presence of the carboxylic acid group is not essential for affinity, it is important in determining the binding cooperativity with ACh. Whilst an 8-methoxy substituent is generally detrimental towards binding cooperativity with ACh, the corresponding 5-methoxy substituent is better tolerated. Furthermore, the 5-position is able to tolerate both hydrogen bond donating (phenol) and accepting (fluoro and methoxy) as well as non-hydrogen bonding groups (hydrogen atom), whilst still maintaining appreciable affinity for the receptor and binding cooperativity with ACh. Overall, substituents at the 5- and 8- positions seem to be more important in tuning the intrinsic efficacy, whereas changing the *N*-(4-methoxy)benzyl group to *N*-(4-phenyl)benzyl tended to improve affinity for the receptor without improving cooperative binding with ACh.

1
2
3 Our series of novel amide derivatives (**8a-h**, **10a-b** and **11**) revealed that the presence of a
4 hydrogen bond donor group, rather than a carboxylic acid functionality may be of importance for
5 binding cooperativity with ACh, though amide derivatives did suffer a reduction in this parameter
6 compared to **5a**. Notably, **8f** only displayed a small drop in binding cooperativity with ACh, relative
7 to parent compound **5a**. The presence of a secondary alcohol group on the cyclohexylamide
8 substituent may allow for further hydrogen bond or polar interactions. Furthermore, the orientation
9 of the amide substituent seems key as the more flexible **10b** exhibited significantly reduced binding
10 cooperativity with ACh compared to **8f**. Further evaluation of **8f** revealed it to be the only
11 compound in our novel series, which also possessed appreciable functional cooperativity with ACh
12 in the calcium mobilisation assay (i.e. $\log \alpha\beta > \log \alpha$).
13
14
15
16
17
18
19
20
21
22
23
24

25 Isosteric replacement of the carboxylic acid group was tolerated at the level of affinity for the
26 receptor, but caused a reduction in binding cooperativity with ACh. The pK_a of the acidic hydrogen
27 atom does not seem to correlate with the degree of cooperative binding with ACh.
28
29
30
31

32 Though the amide and acid isostere derivatives of **5a** synthesised to date do not improve binding
33 cooperativity with ACh over that observed with **5a**, such groups do allow further elaboration of the
34 core BQCA scaffold, whilst offering potential improvements in terms of ADMET. Furthermore, our
35 findings are in contrast to those recently published,³⁴ which report that functionalization of the
36 carboxylic acid moiety on the quinolone-based scaffold is not tolerated. Indeed, amide **8f** whilst
37 being comparable to the parent acid **5f** in terms of affinity for the receptor and binding cooperativity
38 with ACh, actually exhibits improved intrinsic efficacy, as well as functional cooperativity with
39 ACh in the calcium mobilisation assay.
40
41
42
43
44
45
46
47
48

49 Finally, our investigations into the *N*-alkyl pendant showed that substitution in the 4-position of
50 the benzylic group is the most favourable, and seemingly a range of groups can be accommodated.
51 Gratifyingly, propargylamine derivative **22** retained a similar pharmacological profile to **5a**,
52 indicating a potentially open pocket or area able to tolerate a variety of functional groups and
53 polarities. However, access to this pocket appears to be tightly controlled, as removal of the
54
55
56
57
58
59
60

1
2
3 methylene linker in **26a** and **26b** resulted in complete loss of binding cooperativity with ACh
4
5 without major effect on affinity. The presence of a more bulky aliphatic heterocycle instead of the
6
7 planar aromatic ring present in a benzyl group, again caused severe loss of binding cooperativity
8
9 with ACh over several analogues. This again supports the notion that access to a more open pocket
10
11 is most optimally achieved via a conformationally sensitive linker region, preferring planar
12
13 aromatic groups, hinged through a methylene unit.
14
15

16 In summary, our detailed pharmacological profiling approach to allosteric ligands for the M₁
17
18 muscarinic receptor has demonstrated the subtle tunability of individual ligand parameters through
19
20 chemical modification, which has previously only been described as an overall ‘allosteric potency’
21
22 estimate. This allows a more enriched understanding of the SAR surrounding allosteric ligands,
23
24 bringing us closer to delineating some of the ‘flat’ SAR often encountered in this field.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

EXPERIMENTAL SECTION

Chemistry. Chemicals and solvents were purchased from standard suppliers and used without further purification. Davisil® silica gel (40-63 μm), for flash column chromatography (FCC) was supplied by Grace Davison Discovery Sciences (Victoria, Australia) and deuterated solvents were purchased from Cambridge Isotope Laboratories, Inc. (USA, distributed by Novachem PTY. Ltd, Victoria, Australia).

Unless otherwise stated, reactions were carried out at ambient temperature. All microwave reactions took place in a Biotage Initiator Microwave Synthesiser. Reactions were monitored by thin layer chromatography on commercially available precoated aluminium-backed plates (Merck Kieselgel 60 F₂₅₄). Visualisation was by examination under UV light (254 and 366 nm). General staining carried out with KMnO₄ or phosphomolybdic acid. A solution of Ninhydrin (in ethanol) was used to visualize primary and secondary amines. All organic extracts collected after aqueous work-up procedures were dried over anhydrous MgSO₄ or Na₂SO₄ before gravity filtering and evaporation to dryness. Organic solvents were evaporated *in vacuo* at $\leq 40^\circ\text{C}$ (water bath temperature). Purification using preparative layer chromatography (PLC) was carried out on Analtech preparative TLC plates (200 mm \times 200 mm \times 2 mm).

¹H NMR and ¹³C NMR spectra were recorded on a Bruker Avance Nanobay III 400 MHz Ultrashield Plus spectrometer at 400.13 MHz and 100.62 MHz respectively. Chemical shifts (δ) are recorded in parts per million (ppm) with reference to the chemical shift of the deuterated solvent. Coupling constants (*J*) and carbon-fluorine coupling constants (*J_{CF}*) are recorded in Hz and the significant multiplicities described by singlet (s), doublet (d), triplet (t), quadruplet (q), broad (br), multiplet (m), doublet of doublets (dd), doublet of triplets (dt). Spectra were assigned using appropriate COSY, distortionless enhanced polarisation transfer (DEPT), HSQC and HMBC sequences.

LC-MS were run to verify reaction outcome and purity using an Agilent 6100 Series Single Quad coupled to an Agilent 1200 Series HPLC. The following buffers were used; buffer A: 0.1% formic

1
2
3 acid in H₂O; buffer B: 0.1% formic acid in MeCN. The following gradient was used with a
4
5 Phenomenex Luna 3 μ M C8(2) 15 \times 4.6 mm column, and a flow rate of 0.5 mL/min and total run
6
7 time of 12 min; 0–4 min 95% buffer A and 5% buffer B, 4–7 min 0% buffer A and 100% buffer B,
8
9 7–12 min 95% buffer A and 5% buffer B. Mass spectra were acquired in positive and negative ion
10
11 mode with a scan range of 0–1000 *m/z* at 5V. UV detection was carried out at 254 nm. All retention
12
13 times (*t_R*) are quoted in minutes. All compounds were of > 95% purity.
14
15

16 **General procedure A: Condensation of substituted anilines with diethylethoxymethylene**
17 **malonate.** Aniline and diethylethoxymethylene malonate (1 eq) were heated at 100-120 °C (oil
18 bath) together until TLC analysis (EtOAc/PE 3:7) or LC-MS analysis indicated conversion was
19 complete (1–7 h). The mixture was cooled to rt, or until precipitation was noted. At this point, the
20 mixture was diluted with excess PE, and the resulting precipitate collected by filtration (vacuum),
21 before washing with further PE, and drying.
22
23
24
25
26
27
28

29 **General procedure B: Cyclisation of substituted diethyl 2-**
30 **((phenylamino)methylene)malonates (1a–1d) in Eaton's reagent, to give corresponding ethyl**
31 **4-oxo-1,4-dihydroquinoline-3-carboxylates.** Substituted diethyl 2-
32 ((phenylamino)methylene)malonate was dissolved in Eaton's reagent (a solution of
33 P₂O₅/methanesulfonic acid 1:10 w/w, 1 mL/mmol) and heated at 90-100 °C (oil bath) under an
34 atmosphere of nitrogen gas until TLC analysis (EtOAc) indicated disappearance of starting material
35 (5 h to overnight). The mixture was cooled to 5 °C, before pouring into sat. NaHCO₃ (aq) and stirring
36 for 15 min. The resulting precipitate was isolated by filtration (vacuum) and washed with water,
37 then PE, before drying.
38
39
40
41
42
43
44
45
46
47
48

49 **General procedure C: N-Alkylation of substituted ethyl 4-oxo-1,4-dihydroquinoline-3-**
50 **carboxylates (2a–2e).** Substituted ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylate, K₂CO₃ (1.1-1.3
51 eq), KI (0.1 eq) and the appropriate alkyl halide (1.1-1.3 eq) were stirred in DMF (2-4 mL/mmol) at
52 rt overnight. The reaction was monitored by TLC (EtOAc or EtOAc/DCM 8:2). The reaction
53
54
55
56
57
58
59
60

1
2
3 mixture was poured onto ice/water and the resulting precipitate collected by filtration (vacuum),
4
5 with further washings of water, followed by washings of PE, before drying.
6

7 **General procedure D: Basic hydrolysis of esters to give corresponding carboxylic acids.** The
8 appropriate ester was stirred in THF/H₂O (1:1, 4–10 mL/mmol), with the vessel atmosphere being
9 purged with nitrogen gas. To this was added LiOH.H₂O (2-4 eq), and the mixture stirred at rt
10 overnight. Once TLC analysis indicated disappearance of the starting material, the reaction mixture
11 was diluted with water (to 20 mL) and washed with Et₂O (20 mL). The aqueous layer was carefully
12 acidified (~pH 3) with 2 M HCl_(aq), before extracting with EtOAc (3 × 20 mL). The combined
13 organic layers were washed with brine (20 mL), before concentration under reduced pressure.
14
15
16
17
18
19
20
21
22

23 **General procedure E: Synthesis of amide derivatives of 5,8-difluoro-1-(4-methoxybenzyl)-4-**
24 **oxo-1,4-dihydroquinoline-3-carboxylic acid (5a), through an acid chloride intermediate.** 5,8-
25 Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (**5a**) (1.00 g, 2.90
26 mmol) was dispersed in anhydrous DCM, under an atmosphere of N₂, and cooled to 0 °C, over an
27 ice bath. To this was added oxalyl chloride (0.278 mL, 3.19 mmol, 1.1 eq) and DMF (1 drop). The
28 mixture was stirred over the ice bath for 15 min, before warming to rt, and stirring for 1 h. Oxalyl
29 chloride (0.5 eq) was added, and stirring continued for a further 30 min. One tenth of this batch
30 mixture was then added to a vessel containing the appropriate amine (0.725 mmol, 2.5 eq) in DCM
31 (3 mL). Where the amine was present as the hydrochloride salt, TEA (0.754 mmol, 2.6 eq) were
32 also added. The mixtures were stirred at rt overnight, before diluting with DCM (20 mL), and
33 washing with 2 M HCl_(aq) (20 mL). After concentration of the organic layers, the crude products
34 were further purified by FCC (eluent EtOAc/PE or EtOAc/DCM).
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **General procedure F: HCTU-mediated coupling of 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-**
50 **1,4-dihydroquinoline-3-carboxylic acid (5a) with amines to give the corresponding amide.** 5,8-
51 Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (**5a**) (100 mg, 0.29
52 mmol), HCTU (144 mg, 0.35 mmol, 1.2 eq) and amine (1.2-1.5 eq) were stirred in DMF (2 mL) at
53 rt. To this mixture, was added DIPEA (1.5-3 eq, depending on whether the amine was used in the
54
55
56
57
58
59
60

hydrochloride salt form) in DCM (2 mL), before stirring at rt overnight. DCM was removed from the reaction mixture under reduced pressure, before diluting the residue with 1 M HCl_(aq) (20 mL), and extracting with EtOAc (3 × 20 mL). The combined organic layers were washed with sat. NaHCO₃ (aq) (30 mL), water (30 mL) and brine (30 mL). After concentration of the organic layers, the crude product was further purified by FCC.

Diethyl 2-(((2,5-difluorophenyl)amino)methylene)malonate (1a).³⁵ 2,5-Difluoroaniline (11.79 g, 91.32 mmol) was reacted according to general procedure A to give 22.597 g of off-white crystalline solid (83%). ¹H NMR (400 MHz, CDCl₃) δ 11.06 (d, *J* = 13.1 Hz, 1H), 8.39 (d, *J* = 13.3 Hz, 1H), 7.11 (ddd, *J* = 10.1/9.1/4.8 Hz, 1H), 7.00 (ddd, *J* = 9.2/6.3/2.9 Hz, 1H), 6.76 (dddd, *J* = 9.0/7.6/3.7/2.9 Hz, 1H), 4.33 (q, *J* = 7.1 Hz, 2H), 4.27 (q, *J* = 7.1 Hz, 2H), 1.38 (t, *J* = 7.1 Hz, 3H), 1.34 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 168.52, 165.40, 159.33 (dd, *J*_{CF} = 243.6/2.3 Hz), 150.08, 148.95 (dd, *J*_{CF} = 242.1/2.8 Hz), 129.02 (dd, *J*_{CF} = 12.9/10.3 Hz), 117.17 (dd, *J*_{CF} = 21.4/9.7 Hz), 110.83 (dd, *J*_{CF} = 24.2/7.4 Hz), 103.38 (dd, *J*_{CF} = 28.4/1.5 Hz), 96.42, 60.90, 60.58, 14.53, 14.39; *m/z* MS (TOF ES⁻) C₁₄H₁₄F₂NO₄ [M-H]⁻ calcd 298.1; found 298.0; LC-MS *t*_R: 6.18.

Diethyl 2-(((5-fluoro-2-methoxyphenyl)amino)methylene)malonate (1b). 5-Fluoro-2-methoxyaniline (2.17 g, 15.37 mmol) was reacted according to general procedure A to give 3.387 g of off-white solid (71%). ¹H NMR (400 MHz, CDCl₃) δ 11.09 (d, *J* = 13.5 Hz, 1H), 8.44 (d, *J* = 13.9 Hz, 1H), 6.97 (dd, *J* = 9.4/2.8 Hz, 1H), 6.85 (dd, *J* = 9.0, 4.8 Hz, 1H), 6.76 (ddd, *J* = 8.9/8.0/2.8 Hz, 1H), 4.33 (q, *J* = 7.1 Hz, 2H), 4.26 (q, *J* = 7.1 Hz, 2H), 3.92 (s, 3H), 1.38 (t, *J* = 7.1 Hz, 3H), 1.34 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 168.45, 165.82, 157.56 (d, *J*_{CF} = 239.4 Hz), 149.78, 145.16 (d, *J*_{CF} = 2.3 Hz), 129.85 (d, *J*_{CF} = 10.0 Hz), 112.06 (d, *J*_{CF} = 9.2 Hz), 110.13 (d, *J*_{CF} = 23.0 Hz), 102.04 (d, *J*_{CF} = 27.9 Hz), 95.09, 60.58, 60.37, 56.58, 14.57, 14.44; LC-MS *t*_R: 6.15.

Diethyl 2-(((2-methoxyphenyl)amino)methylene)malonate (1c).³⁶ *ortho*-Anisidine (2.00 g, 16.24 mmol) was reacted according to general procedure A, After reaction completion, addition of PE on cooling caused formation of a dark red oily layer at the bottom of the flask. This was stirred

1
2
3 in PE for 5 min, before allowing full separation to occur, and decanting the top layer. The red oil
4
5 was washed with PE in this manner a further two times before drying under vacuum, causing a
6
7 solidification to occur. Filtration (vacuum) gave 1.155 g of light red solid. The decanted PE
8
9 washings began to show crystal formation. These were collected by filtration (vacuum) and washed
10
11 with PE to give 2.958 g of off-white crystals. Spectral comparison of the two solids indicated both
12
13 were the desired product. Total yield: 4.113 g (86%). ^1H NMR (400 MHz, CDCl_3) δ 11.11 (d, J =
14
15 13.9 Hz, 1H), 8.57 (d, J = 14.0 Hz, 1H), 7.29–7.21 (m, 1H), 7.12–7.07 (m, 1H), 6.99 (ddd, J =
16
17 7.6/7.6/ 0.9 Hz, 1H), 6.94 (dd, J = 8.1/1.2 Hz, 1H), 4.33 (q, J = 7.1 Hz, 2H), 4.25 (q, J = 7.1 Hz,
18
19 2H), 3.94 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H), 1.33 (t, J = 7.1 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ
20
21 168.67, 166.17, 150.55, 149.08, 128.90, 124.94, 121.33, 114.47, 111.38, 93.90, 60.40, 60.19, 56.08,
22
23 14.59, 14.48; m/z MS (TOF ES^+) $\text{C}_{15}\text{H}_{19}\text{NNaO}_5$ $[\text{M}+\text{Na}]^+$ calcd 316.3; found 316.2; LC-MS t_{R} :
24
25 6.08.
26
27
28

29
30 **Diethyl 2-(((2-chloro-5-methoxyphenyl)amino)methylene)malonate (1d).** 6-Chloro-*m*-
31
32 anisidine hydrochloride (3.00 g, 15.46 mmol), Et_3N (2.37 mL, 17.00 mmol, 1.1 eq) and
33
34 diethylethoxymethylene malonate (3.34 g, 15.46 mmol, 1eq) were stirred together under a reflux
35
36 condenser at 100 °C for 1 h. TLC analysis (EtOAc/PE 3:7) indicated disappearance of starting
37
38 aniline. The mixture was cooled to rt overnight, before partitioning between water (100 mL) and
39
40 Et_2O (100 mL). The aqueous layer was extracted with EtOAc (100 mL), and the combined organic
41
42 layers washed with water (100 mL) then brine (50 mL), before drying over MgSO_4 and
43
44 concentrating to give a crude purple solid. This was dispersed in PE, sonicated, then filtered
45
46 (vacuum), with washings of PE, to give 4.024 g (79%) of purple solid. ^1H NMR (400 MHz, CDCl_3)
47
48 δ 11.24 (d, J = 13.1 Hz, 1H), 8.47 (d, J = 13.2 Hz, 1H), 7.31 (d, J = 8.8 Hz, 1H), 6.82 (d, J = 2.7
49
50 Hz, 1H), 6.62 (dd, J = 8.9/2.7 Hz, 1H), 4.34 (q, J = 7.1 Hz, 2H), 4.26 (q, J = 7.1 Hz, 2H), 3.83 (s,
51
52 3H), 1.38 (t, J = 7.1 Hz, 3H), 1.34 (t, J = 7.1 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 168.48,
53
54 165.85, 159.62, 150.24, 137.13, 130.80, 115.35, 110.25, 102.05, 95.82, 60.78, 60.49, 55.90, 14.54,
55
56 14.46; m/z MS (TOF ES^-) $\text{C}_{15}\text{H}_{17}\text{ClNO}_5$ $[\text{M}-\text{H}]^-$ calcd 326.8; found 326.0; LC-MS t_{R} : 6.33.
57
58
59
60

1
2
3 **Ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (2a)**.³⁵ Diethyl 2-(((2,5-
4 difluorophenyl)amino)methylene)malonate (**1a**) (26.07 g, 87.12 mmol) was cyclised according to
5 general procedure B to give 18.54 g of yellow solid (84%). ¹H NMR (400 MHz, DMSO) δ 8.62 (s,
6 1H), 7.27 (ddd, *J* = 10.4/8.8/4.2 Hz, 1H), 6.79 (ddd, *J* = 12.3/8.7/3.9 Hz, 1H), 4.17 (q, *J* = 7.1 Hz,
7 2H), 1.27 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (101 MHz, DMSO) δ 173.24, 166.79, 156.87 (dd, *J*_{CF} =
8 256.0/2.8 Hz), 153.47, 152.94 (dd, *J*_{CF} = 247.2/3.7 Hz), 140.68 (d, *J*_{CF} = 12.5 Hz), 119.64 (d, *J*_{CF} =
9 4.6 Hz), 114.04 (dd, *J*_{CF} = 21.5/11.1 Hz), 108.79, 106.88 (dd, *J*_{CF} = 24.5/7.7 Hz), 58.59, 14.46; *m/z*
10 MS (TOF ES⁻) C₁₂H₈F₂NO₃ [M-H]⁻ calcd 252.1; found 252.1; MS (TOF ES⁺) C₁₂H₁₀F₂NO₃ [MH]⁺
11 calcd 254.1; found 254.1; LC-MS *t*_R: 4.55.

12
13
14
15
16
17
18
19
20
21
22
23 **Ethyl 5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (2b)**. Diethyl 2-(((5-
24 fluoro-2-methoxyphenyl)amino)methylene)malonate (**1b**) (3.303 g, 10.61 mmol) was cyclised
25 according to general procedure B. On pouring the cooled reaction mixture on to sat. NaHCO₃ (aq),
26 precipitation did not occur. The aqueous mixture was extracted with EtOAc (3 x 100 mL), and the
27 combined organic extracts washed with brine (120 mL). The organic layers were then concentrated
28 under reduced pressure to give a crude orange solid. This was redissolved in the minimum amount
29 of EtOAc, before adding enough PE to effect precipitation. The resultant solid was collected by
30 filtration (vacuum), to give 1.226 g of brown solid (44%). ¹H NMR (400 MHz, DMSO) δ 11.81 (d,
31 *J* = 6.0 Hz, 1H), 8.25 (d, *J* = 6.8 Hz, 1H), 7.27 (dd, *J* = 8.9/3.8 Hz, 1H), 7.04 (dd, *J* = 11.9/8.9 Hz,
32 1H), 4.20 (q, *J* = 7.1 Hz, 2H), 3.97 (s, 3H), 1.26 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (101 MHz, DMSO) δ
33 172.12, 164.34, 154.32 (d, *J*_{CF} = 252.6 Hz), 144.55 (d, *J*_{CF} = 3.5 Hz), 143.62, 130.73 (d, *J*_{CF} = 3.7
34 Hz), 117.11 (d, *J*_{CF} = 9.6 Hz), 112.47 (d, *J*_{CF} = 9.6 Hz), 111.70, 109.93 (d, *J*_{CF} = 22.9 Hz), 59.72,
35 56.59, 14.26; *m/z* MS (TOF ES⁺) C₁₃H₁₃FNO₄ [MH]⁺ calcd 266.1; found 266.1; LC-MS *t*_R: 4.75.

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52 **Ethyl 8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (2c)**. Diethyl 2-(((2-
53 methoxyphenyl)amino)methylene)malonate (**1c**) (3.97 g, 13.53 mmol) was cyclised according to
54 general procedure B. The resulting crude solid was recrystallised from EtOH/water, giving two
55 crops: 994 mg of pale brown solid and 944 mg of brown solid. Total yield = 1.938 g (58%). ¹H
56
57
58
59
60

1
2
3 NMR (400 MHz, DMSO) δ 11.91 (s, 1H), 8.34 (d, $J = 5.6$ Hz, 1H), 7.71 (d, $J = 6.2$ Hz, 1H), 7.44 –
4
5 7.26 (m, 2H), 4.21 (q, $J = 7.0$ Hz, 2H), 4.00 (s, 3H), 1.27 (t, $J = 7.0$ Hz, 3H); ^{13}C NMR (101 MHz,
6
7 DMSO) δ 173.20, 164.66, 148.71, 144.03, 129.34, 128.17, 124.66, 116.78, 112.24, 109.99, 59.61,
8
9 56.36, 14.33; m/z MS (TOF ES⁺) C₁₃H₁₄NO₄ [MH]⁺ calcd 248.3; found 248.1; LC-MS t_R : 4.79.

10
11 **Ethyl 8-chloro-5-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (2d).**³⁷ Diethyl 2-(((2-
12
13 chloro-5-methoxyphenyl)amino)methylene)malonate (**1d**) (3.983 g, 12.15 mmol) was cyclised
14
15 according to general procedure B. On pouring the cooled reaction mixture on to sat. NaHCO₃ (aq),
16
17 precipitation did not occur. The aqueous mixture was extracted with EtOAc (3 × 50 mL). TLC
18
19 analysis (EtOAc) of the aqueous and organic layers indicated product was still present in the
20
21 aqueous layer. This was concentrated, and saturated with NaCl, before re-extraction with EtOAc (3
22
23 x 50 mL). Concentration of both organic layers found them to be impure, so they were combined,
24
25 concentrated and further purified by FCC (eluent MeOH/EtOAc/PE 0:50:50 to 0:100:0, then up to
26
27 2:98:0) to give 1.213 g of brown solid (35%). ^1H NMR (400 MHz, DMSO) δ 11.36 (s, 1H), 8.23 (s,
28
29 1H), 7.75 (d, $J = 8.9$ Hz, 1H), 6.90 (d, $J = 8.9$ Hz, 1H), 4.19 (q, $J = 7.1$ Hz, 2H), 3.83 (s, 3H), 1.26
30
31 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (101 MHz, DMSO) δ 172.71, 164.49, 159.09, 149.13, 143.24, 132.62,
32
33 121.34, 115.93, 112.29, 106.82, 59.75, 56.09, 14.23; m/z MS (TOF ES⁺) C₁₃H₁₃ClNO₄ [MH]⁺ calcd
34
35 282.7; found 282.1; LC-MS t_R : 4.88.

36
37 **Ethyl 5-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (2e).**³⁷ Ethyl 8-chloro-5-methoxy-
38
39 4-oxo-1,4-dihydroquinoline-3-carboxylate (**2d**) (500 mg, 1.78 mmol) was dispersed in EtOH (10
40
41 mL), before sonication to degas the solvent. The vessel was evacuated and filled with nitrogen,
42
43 before addition of 10% Pd/C (50 mg), with care. After resealing, the vessel underwent three cycles
44
45 of evacuation and filling with hydrogen gas (balloon), before stirring at rt overnight. TLC analysis
46
47 (MeOH/DCM 1:9) indicated only partial progression, so EtOH (10 mL) was added to aid
48
49 dissolution of the starting material, and hydrogenation continued for a further 2 nights. After this
50
51 time 10% Pd/C (50 mg) was added with care (after evacuation of the vessel and filling with
52
53 nitrogen gas), and hydrogenation continued. After a total of 5 nights of stirring, no starting material
54
55
56
57
58
59
60

1
2
3 was evident by TLC. The mixture was diluted with DCM, and filtered through a bed of celite, with
4
5 further washings of DCM. Concentration of the filtrate gave 457 mg of yellow solid (quantitative
6
7 yield). ¹H NMR (400 MHz, DMSO) δ 8.36 (s, 1H), 7.58 (dd, *J* = 8.2/8.2 Hz, 1H), 7.33 (dd, *J* =
8
9 8.3/0.8 Hz, 1H), 7.15 (dd, *J* = 8.2/0.6 Hz, 1H), 6.88 (d, *J* = 8.1 Hz, 1H), 4.19 (q, *J* = 7.1 Hz, 2H),
10
11 3.82 (s, 3H), 1.27 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (101 MHz, DMSO) δ 173.26, 165.01, 159.78,
12
13 143.15, 141.64, 133.04, 116.86, 111.40, 110.48, 106.35, 59.64, 55.86, 14.28; *m/z* MS (TOF ES⁺)
14
15 C₁₃H₁₄NO₄ [MH]⁺ calcd 248.3; found 248.2; LC-MS *t*_R: 4.53.

16
17
18 **Ethyl 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (3a).**⁸
19
20 Ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (**2a**) (3.00 g, 11.85 mmol), was
21
22 alkylated with 4-methoxybenzyl chloride, according to general procedure C. After the initial period
23
24 of overnight stirring, further K₂CO₃ (0.5 eq) and 4-methoxybenzyl chloride (0.5 eq) were added and
25
26 stirring continued for a further overnight period. Due to difficulty filtering the product after pouring
27
28 onto ice water, EtOAc (500 mL) was added to redissolve the wet crude material, and this was
29
30 washed with water (100 mL) and brine (100 mL), before concentration under reduced pressure.
31
32 Crude residue was redissolved in the minimum amount of EtOAc, and precipitation effected by
33
34 addition of PE. The desired product was isolated by filtration (vacuum) to give 3.074 g of brown
35
36 solid (69%). ¹H NMR (400 MHz, CDCl₃) δ 8.42 (s, 1H), 7.32–7.15 (m, 1H), 7.08 (d, *J* = 8.4 Hz,
37
38 2H), 6.96 (ddd, *J* = 10.4/9.0/3.4 Hz, 1H), 6.86 (d, *J* = 8.8 Hz, 2H), 5.43 (d, *J* = 2.8 Hz, 2H), 4.39 (q,
39
40 *J* = 7.1 Hz, 2H), 3.78 (s, 3H), 1.40 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 174.20,
41
42 165.33, 161.99 (d, *J*_{CF} = 233.7 Hz), 159.88, 151.22, 150.53 (d, *J*_{CF} = 231.7 Hz), 127.89, 127.88,
43
44 127.17 (d, *J*_{CF} = 1.0 Hz), 125.16 (d, *J*_{CF} = 7.5 Hz), 120.04, 114.64, 113.09, 112.30 (d, *J*_{CF} = 25.2
45
46 Hz), 61.39, 60.64 (d, *J*_{CF} = 17.3 Hz), 55.46, 14.52; *m/z* MS (TOF ES⁻) C₂₀H₁₇F₂NNaO₄ [M+Na]⁺
47
48 calcd 396.1; found 396.1; LC-MS *t*_R: 5.62.

49
50
51
52
53
54 **Ethyl 5-fluoro-8-methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate**
55
56 (**3b**). Ethyl 5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (**2b**) (200 mg, 0.75
57
58 mmol) was alkylated with 4-methoxybenzyl chloride, according to general procedure C. After the
59
60

1
2
3 initial period of overnight stirring, further K_2CO_3 (0.3 eq) and 4-methoxybenzyl chloride (0.3 eq)
4
5 were added and stirring continued for a further overnight period. The desired product was isolated
6
7 by filtration as described, to give 160 mg of yellow solid (58%). 1H NMR (400 MHz, $CDCl_3$) δ 8.38
8
9 (s, 1H), 7.06–6.88 (m, 4H), 6.87–6.75 (m, 2H), 5.61 (s, 2H), 4.37 (q, $J = 7.1$ Hz, 2H), 3.76 (s, 3H),
10
11 3.72 (s, 3H), 1.39 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 173.47, 165.68, 159.41,
12
13 156.53 (d, $J_{CF} = 258.3$ Hz), 151.84, 145.93 (d, $J_{CF} = 3.9$ Hz), 131.71, 128.78, 127.47, 121.11 (d, J_{CF}
14
15 = 7.1 Hz), 115.03 (d, $J_{CF} = 10.2$ Hz), 114.41, 112.67, 112.13 (d, $J_{CF} = 23.8$ Hz), 61.41, 61.15,
16
17 56.79, 55.42, 14.54; m/z MS (TOF ES^+) $C_{21}H_{21}FNO_5$ $[MH]^+$ calcd 386.4; found 386.2; LC-MS t_R :
18
19 5.62.
20
21

22
23 **Ethyl 8-methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (3c).** Ethyl
24
25 8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (**2c**) (500 mg, 2.02 mmol) was alkylated with
26
27 4-methoxybenzyl chloride, according to general procedure C, to give 578 mg of pale brown solid.
28
29 This was further purified by FCC (eluent EtOAc/PE 0:100 to 100:0) to give 529 mg of light brown
30
31 solid (71%). 1H NMR (400 MHz, $CDCl_3$) δ 8.47 (s, 1H), 8.16 (dd, $J = 8.1/1.3$ Hz, 1H), 7.31 (t, $J =$
32
33 8.0 Hz, 1H), 7.06 (dd, $J = 7.9/1.0$ Hz, 1H), 6.99 (d, $J = 8.7$ Hz, 2H), 6.81 (d, $J = 8.7$ Hz, 2H), 5.66
34
35 (s, 2H), 4.38 (q, $J = 7.1$ Hz, 2H), 3.75 (s, 6H), 1.40 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (101 MHz,
36
37 $CDCl_3$) δ 174.06, 165.96, 159.29, 152.08, 150.02, 131.96, 130.27, 129.12, 127.36, 125.67, 120.06,
38
39 114.82, 114.33, 110.83, 61.50, 60.99, 56.37, 55.38, 14.55; m/z MS (TOF ES^+) $C_{21}H_{22}NO_5$ $[MH]^+$
40
41 calcd 368.4; found 368.2; LC-MS t_R : 5.65.
42
43
44

45
46 **Ethyl 5-methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (3d).** Ethyl
47
48 5-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (**2e**) (100 mg, 0.40 mmol), was alkylated
49
50 with 4-methoxybenzyl chloride, according to general procedure C, to give 66 mg of off-white solid
51
52 (45%). 1H NMR (400 MHz, $CDCl_3$) δ 8.42 (s, 1H), 7.41 (dd, $J = 8.4/8.4$ Hz, 1H), 7.08 (d, $J = 8.7$
53
54 Hz, 2H), 6.93 – 6.82 (m, 3H), 6.79 (d, $J = 8.2$ Hz, 1H), 5.24 (s, 2H), 4.38 (q, $J = 7.1$ Hz, 2H), 3.95
55
56 (s, 3H), 3.78 (s, 3H), 1.39 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 174.91, 166.36,
57
58 161.75, 159.80, 148.37, 142.00, 132.85, 127.64, 126.42, 119.63, 114.82, 113.30, 108.49, 106.98,
59
60

60.98, 57.61, 56.49, 55.47, 14.61; m/z MS (TOF ES⁺) C₂₁H₂₂NO₅ [MH]⁺ calcd 368.4; found 368.2; LC-MS t_R : 5.46.

Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (4a).⁹ Ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (**2a**) (500 mg, 1.97 mmol), was alkylated with 4-phenylbenzyl bromide, according to general procedure C, to give 420 mg of yellow solid (51%). ¹H NMR (400 MHz, CDCl₃) δ 8.46 (s, 1H), 7.64–7.49 (m, 4H), 7.48–7.39 (m, 2H), 7.38–7.30 (m, 1H), 7.29–7.22 (m, 1H), 7.20 (d, J = 8.1 Hz, 2H), 6.97 (ddd, J = 10.3/9.1/3.4 Hz, 1H), 5.54 (d, J = 2.8 Hz, 2H), 4.40 (q, J = 7.1 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 165.25, 156.74 (d, J_{CF} = 244.7 Hz), 151.39, 147.77 (dd, J_{CF} = 241.9/4.0 Hz), 141.67, 140.25, 134.33, 130.16, 129.02, 127.96, 127.83, 127.19, 126.65, 120.72 (d, J_{CF} = 7.8 Hz), 120.06 (dd, J_{CF} = 25.8/10.6 Hz), 113.31, 112.41 (dd, J_{CF} = 24.6, 8.2 Hz), 61.43, 60.83 (d, J_{CF} = 17.2 Hz), 14.53; m/z MS (TOF ES⁺) C₂₅H₂₀F₂NO₃ [MH]⁺ calcd 420.4; found 420.2; LC-MS t_R : 6.08.

Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (4b). Ethyl 5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (**2b**) (500 mg, 1.89 mmol) was alkylated with 4-phenylbenzyl bromide, according to general procedure C. After the initial period of overnight stirring, further K₂CO₃ (0.3 eq) and 4-phenylbenzyl chloride (0.3 eq) were added and stirring continued for a further overnight period. The desired product was isolated by filtration as described, to give 258 mg of pale yellow solid (32%). ¹H NMR (400 MHz, CDCl₃) δ 8.41 (s, 1H), 7.62–7.49 (m, 4H), 7.43 (dd, J = 10.3/4.8 Hz, 2H), 7.34 (ddd, J = 7.3/3.8/1.2 Hz, 1H), 7.12 (d, J = 8.3 Hz, 2H), 7.05 – 6.91 (m, 2H), 5.72 (s, 2H), 4.39 (q, J = 7.1 Hz, 2H), 3.69 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 173.44, 165.65, 156.58 (d, J_{CF} = 258.4 Hz), 152.00, 145.89 (d, J_{CF} = 3.9 Hz), 140.94, 140.34, 135.92, 131.75 (d, J_{CF} = 1.6 Hz), 129.00, 127.72, 127.69, 127.12, 126.31, 121.08 (d, J_{CF} = 7.2 Hz), 115.14 (d, J_{CF} = 10.1 Hz), 112.83, 112.22 (d, J_{CF} = 23.7 Hz), 61.74, 61.21, 56.82, 14.55; m/z MS (TOF ES⁺) C₂₆H₂₃FNO₄ [MH]⁺ calcd 432.5; found 432.2; LC-MS t_R : 6.08.

Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (4c). Ethyl 8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (**2c**) (500 mg, 2.02 mmol) was alkylated with 4-phenylbenzyl bromide, according to general procedure C. After the initial period of overnight stirring, further K_2CO_3 (0.3 eq) and 4-phenylbenzyl chloride (0.3 eq) were added and stirring continued for a further overnight period. The desired product was isolated by filtration as described, to give 718 mg of yellow solid (86%). 1H NMR (400 MHz, $CDCl_3$) δ 8.51 (s, 1H), 8.20 (dd, $J = 8.1/1.3$ Hz, 1H), 7.62–7.47 (m, 4H), 7.42 (dd, $J = 7.5/7.5$ Hz, 2H), 7.38–7.29 (m, 2H), 7.12 (d, $J = 8.2$ Hz, 2H), 7.08 (dd, $J = 8.0/1.1$ Hz, 1H), 5.77 (s, 2H), 4.41 (q, $J = 7.1$ Hz, 2H), 3.73 (s, 3H), 1.42 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 174.08, 165.99, 152.30, 150.02, 140.82, 140.40, 136.27, 131.97, 130.36, 128.98, 127.66, 127.64, 127.11, 126.25, 125.79, 120.19, 114.95, 111.05, 61.86, 61.10, 56.43, 14.59; m/z MS (TOF ES⁺) $C_{26}H_{24}NO_4$ [MH]⁺ calcd 414.5; found 414.2; LC-MS t_R : 6.12.

Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (4d). Ethyl 5-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (**2e**) (250 mg, 1.01 mmol) was alkylated with 4-phenylbenzyl bromide, according to general procedure C. The filtered crude solid was further purified by FCC (EtOAc/PE 0:100 to 100:0) to give 201 mg of pale yellow solid (48%). 1H NMR (400 MHz, $CDCl_3$) δ 8.47 (s, 1H), 7.66–7.49 (m, 4H), 7.49–7.39 (m, 3H), 7.39–7.29 (m, 1H), 7.22 (d, $J = 8.4$ Hz, 2H), 6.86 (d, $J = 8.2$ Hz, 1H), 6.81 (d, $J = 8.2$ Hz, 1H), 5.35 (s, 2H), 4.39 (q, $J = 7.1$ Hz, 2H), 3.96 (s, 3H), 1.40 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 174.88, 166.28, 161.79, 148.51, 141.99, 141.58, 140.24, 133.59, 132.96, 129.02, 128.09, 127.82, 127.17, 126.58, 119.59, 113.48, 108.50, 107.06, 61.01, 57.81, 56.51, 14.62; m/z MS (TOF ES⁺) $C_{26}H_{24}NO_4$ [MH]⁺ calcd 414.5; found 414.2; LC-MS t_R : 5.98.

5,8-Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (5a). Ethyl 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (**3a**) (2.37 g, 6.34 mmol) was dissolved in 1,4-dioxane (15 mL), before adding 2 M $HCl_{(aq)}$. The mixture was heated under reflux for 2 h. TLC analysis (EtOAc) indicated complete conversion had taken place. The

1
2
3 mixture was cooled to rt, dilute with water (50 mL) and the precipitate filtered, then washed with
4
5 water and petroleum ether 40-60. The crude collected precipitate was found to contain a mixture of
6
7 the desired acid, as well as some debenzylated derivative. The desired compound was obtained by
8
9 washing the solid with DCM, and concentration of the filtrate. This gave 336 mg (24%) of the
10
11 debenzylated side-product as a white solid (precipitate), and 1.417g (65%) of the desired compound
12
13 as a pale yellow solid (DCM washings). ¹H NMR (400 MHz, DMSO) δ 14.76 (s, 1H), 9.11 (s, 1H),
14
15 7.77 (ddd, *J* = 13.8/9.1/4.4 Hz, 1H), 7.39 (ddd, *J* = 11.1/9.1/3.2 Hz, 1H), 7.12 (d, *J* = 8.5 Hz, 2H),
16
17 6.99–6.78 (m, 2H), 5.78 (d, *J* = 3.7 Hz, 2H), 3.71 (s, *J* = 4.7 Hz, 3H); ¹³C NMR (101 MHz, DMSO)
18
19 δ 176.96, 165.21, 158.89, 157.12 (dd, *J*_{CF} = 261.1/3.1 Hz), 152.20, 147.61 (dd, *J*_{CF} = 248.1/4.0 Hz),
20
21 130.14 (dd, *J*_{CF} = 9.0/2.8 Hz), 127.91 (d, *J*_{CF} = 1.9 Hz), 127.59, 121.86 (dd, *J*_{CF} = 26.0/10.8 Hz),
22
23 117.51 (d, *J*_{CF} = 9.1 Hz), 114.17, 113.27 (dd, *J*_{CF} = 23.6/8.4 Hz), 109.24, 60.22 (d, *J*_{CF} = 16.5 Hz),
24
25 55.06; *m/z* MS (TOF ES⁻) C₁₈H₁₂F₂NO₄ [M-H]⁻ calcd 344.3; found 344.1; LC-MS *t*_R: 5.61.

26
27
28
29 **5-Fluoro-8-methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid**
30
31 **(5b)**. Ethyl 5-fluoro-8-methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate
32
33 **(3b)** (121 mg, 0.31 mmol) was hydrolysed according to general procedure D. After initial overnight
34
35 stirring, further LiOH.H₂O (1eq) was added, and stirring continued for a further hour before
36
37 workup. The product was isolated as 58 mg of pale brown solid (59%). ¹H NMR (400 MHz,
38
39 DMSO) δ 15.07 (s, 1H), 9.04 (s, 1H), 7.45 (dd, *J* = 9.1, 4.5 Hz, 1H), 7.33 (dd, *J* = 11.2, 9.1 Hz, 1H),
40
41 7.04 (d, *J* = 8.7 Hz, 2H), 6.86 (t, *J* = 5.8 Hz, 2H), 5.94 (s, 2H), 3.79 (s, 3H), 3.69 (s, 3H); ¹³C NMR
42
43 (101 MHz, DMSO) δ 177.48, 165.54, 158.64, 154.52 (d, *J*_{CF} = 256.2 Hz), 152.27, 146.40 (d, *J*_{CF} =
44
45 3.5 Hz), 131.22 (d, *J*_{CF} = 1.5 Hz), 128.95, 127.65, 117.48 (d, *J*_{CF} = 8.6 Hz), 117.11 (d, *J*_{CF} = 9.9
46
47 Hz), 113.99, 113.15 (d, *J*_{CF} = 22.6 Hz), 108.71, 61.32, 56.89, 55.00; *m/z* MS (TOF ES⁻)
48
49 C₁₉H₁₅FNO₅ [M-H]⁻ calcd 356.1; found 356.0; LC-MS *t*_R: 5.87.

50
51
52
53 **8-Methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (5c)**. Ethyl 8-
54
55 methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate **(3c)** (105 mg, 0.29
56
57 mmol) was hydrolysed according to general procedure D. After initial overnight stirring, further
58
59
60

LiOH.H₂O (1.5 eq) was added, and stirring continued for a further overnight period before workup. In this case, the acidified aqueous layer was extracted with DCM (3 x 20 mL) to obtain the free acid. The product was isolated as 109 mg of pale brown solid (98%). ¹H NMR (400 MHz, CDCl₃) δ 14.95 (s, 1H), 8.74 (s, 1H), 8.16 (dd, *J* = 8.1/1.4 Hz, 1H), 7.47 (dd, *J* = 8.1 Hz, 1H), 7.21 (dd, *J* = 8.0/1.3 Hz, 1H), 7.06–6.90 (m, 2H), 6.88–6.72 (m, 2H), 5.80 (s, 2H), 3.83 (s, 3H), 3.77 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 178.35, 167.12, 159.63, 151.30, 150.46, 130.88, 129.22, 128.23, 127.53, 126.98, 119.17, 115.89, 114.55, 108.76, 62.54, 56.55, 55.44; *m/z* MS (TOF ES⁺) C₁₉H₁₈NO₅ [MH]⁺ calcd 340.1; found 340.2; LC-MS *t*_R: 5.67.

5-Methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (5d). Ethyl 5-methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (**3d**) (49 mg, 0.13 mmol) was hydrolysed according to general procedure D. After initial overnight stirring, further LiOH.H₂O (1 eq) was added, and stirring continued for a further hour before workup. The product was isolated as 22 mg of yellow solid (49%). ¹H NMR (400 MHz, CD₃CN) δ 8.83 (s, 1H), 7.65 (dd, *J* = 8.5 Hz, 1H), 7.30 – 7.12 (m, 3H), 7.02 (d, *J* = 8.3 Hz, 1H), 6.90 (d, *J* = 8.7 Hz, 2H), 5.48 (s, 2H), 3.93 (s, 3H), 3.75 (s, 3H); ¹³C NMR (101 MHz, CD₃CN) δ 180.60, 167.96, 162.24, 160.73, 149.65, 143.38, 135.54, 129.30, 127.57, 117.63, 115.37, 110.63, 110.28, 108.69, 58.64, 57.00, 55.99; *m/z* MS (TOF ES⁺) C₁₉H₁₈NO₅ [MH]⁺ calcd 340.1; found 340.2; LC-MS *t*_R: 5.34.

1-([1,1'-Biphenyl]-4-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (6a).³⁸ Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (**4a**) (100 mg, 0.24 mmol) was dispersed in 1,4-dioxane/1M HCl_(aq) (1:1, 2 mL) and heated at 80 °C for 3.5 h, before stirring at rt overnight. The mixture was then refluxed for a further 2.5 h, before TLC analysis (MeOH/DCM 2:98) indicated starting material had been consumed. The mixture was diluted with water, and the resultant precipitate collected by filtration (vacuum), before washing with further water and PE, then drying. This gave 82 mg of pale yellow solid (88%). ¹H NMR (400 MHz, DMSO) δ 14.79 (s, 1H), 9.19 (s, 1H), 7.79 (ddd, *J* = 13.8, 9.1, 4.4 Hz, 1H), 7.70–7.52 (m, 4H), 7.50–7.31 (m, 4H), 7.26 (d, *J* = 8.2 Hz, 2H), 5.92 (d, *J* = 3.9 Hz, 2H); ¹³C NMR (101 MHz,

1
2
3 DMSO) δ 177.04, 165.23, 157.18 (d, $J_{CF} = 262.1$ Hz), 152.57, 147.37 (d, $J_{CF} = 293.5$ Hz), 139.60,
4
5 139.47, 135.62 (d, $J_{CF} = 2.1$ Hz), 130.29, 128.93, 127.56, 127.06, 126.61, 126.37, 122.04 (dd, $J_{CF} =$
6
7 22.5, 11.6 Hz), 117.55 (d, $J_{CF} = 9.0$ Hz), 113.31 (dd, $J_{CF} = 23.3, 8.5$ Hz), 109.40, 60.44 (d, $J_{CF} =$
8
9 15.9 Hz); m/z MS (TOF ES⁺) C₂₃H₁₆F₂NO₃ [MH]⁺ calcd 392.3; found 392.1; LC-MS t_R 6.05.

11 **1-([1,1'-Biphenyl]-4-ylmethyl)-5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (6b).**
12 Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-
13 carboxylate (**4b**) (214 mg, 0.50 mmol) was hydrolysed according to general procedure D. After
14 initial overnight stirring, further LiOH.H₂O (1 eq) was added, and stirring continued for a further
15 hour before workup. The isolated product was found to contain a small amount of starting material,
16 so the crude product was dispersed in 1,4-dioxane/H₂O (1:1, 2 mL), and heated at 80 °C for 3.5
17 hour, followed stirring at rt overnight, then reflux for 8.5 h. The desired product was isolated by
18 filtration, after dilution of the reaction mixture with water, to give 156 mg of pink solid (77%). ¹H
19 NMR (400 MHz, DMSO) δ 15.08 (s, 1H), 9.09 (s, 1H), 7.69–7.55 (m, 4H), 7.51 – 7.40 (m, 3H),
20 7.39 – 7.28 (m, 2H), 7.18 (d, $J = 8.3$ Hz, 2H), 6.06 (s, 2H), 3.75 (s, 3H); ¹³C NMR (101 MHz,
21 DMSO) δ 177.54, 165.55, 154.60 (d, $J_{CF} = 256.2$ Hz), 152.58, 146.37 (d, $J_{CF} = 3.4$ Hz), 139.46,
22 139.20, 136.60, 131.36, 128.91, 127.50, 126.85, 126.54, 126.48, 117.53, 117.29 (d, $J_{CF} = 10.1$ Hz),
23 113.20 (d, $J_{CF} = 22.9$ Hz), 108.81, 61.67, 56.95; m/z MS (TOF ES⁺) C₂₄H₁₉FNO₄ [MH]⁺ calcd
24 404.1; found 404.2; LC-MS t_R : 6.06.

25 **1-([1,1'-Biphenyl]-4-ylmethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid**
26 (**6c**). Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate
27 (**4c**) (310 mg, 0.75 mmol), was hydrolysed by the same procedure, as described for the hydrolysis of
28 ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate
29 (**4b**) in the synthesis of 1-([1,1'-biphenyl]-4-ylmethyl)-5-fluoro-8-methoxy-4-oxo-1,4-
30 dihydroquinoline-3-carboxylic acid (**6b**) above. The crude product after acidic hydrolysis required
31 washings of DCM/PE (1:1) to remove residual starting material. The title compound was isolated as
32 180 mg of white solid (62%). ¹H NMR (400 MHz, DMSO) δ 15.16 (s, 1H), 9.14 (s, 1H), 8.01 (dd, J
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 = 8.0, 1.4 Hz, 1H), 7.67 – 7.53 (m, 5H), 7.48 (dd, $J = 8.1, 1.3$ Hz, 1H), 7.43 (dd, $J = 7.6, 7.6$ Hz,
4 2H), 7.38–7.30 (m, 1H), 7.18 (d, $J = 8.3$ Hz, 2H), 6.10 (s, 2H), 3.80 (s, 3H); ^{13}C NMR (101 MHz,
5 DMSO) δ 177.50, 165.82, 152.15, 150.35, 139.47, 139.21, 136.78, 130.28, 128.90, 128.06, 127.49,
6 127.27, 126.86, 126.54, 126.50, 117.59, 116.71, 107.65, 61.54, 56.60; m/z MS (TOF ES⁺)
7 $\text{C}_{24}\text{H}_{20}\text{NO}_4$ [MH]⁺ calcd 386.1; found 386.2; LC-MS t_{R} : 6.15.

14 **1-([1,1'-Biphenyl]-4-ylmethyl)-5-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid**
15
16 **(6d)**. Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate
17 **(4d)** (140 mg, 0.34 mmol), was hydrolysed by the same procedure, as described for the hydrolysis
18 of ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-
19 carboxylate **(4b)** in the synthesis of 1-([1,1'-biphenyl]-4-ylmethyl)-5-fluoro-8-methoxy-4-oxo-1,4-
20 dihydroquinoline-3-carboxylic acid **(6b)** above. The title compound was isolated as 118 mg of pale
21 yellow solid (90%). ^1H NMR (400 MHz, DMSO) δ 9.22 (s, 1H), 7.74 (dd, $J = 8.5$ Hz, 1H), 7.68–
22 7.55 (m, 4H), 7.44 (dd, $J = 7.6$ Hz, 2H), 7.39–7.24 (m, 4H), 7.10 (d, $J = 8.3$ Hz, 1H), 5.84 (s, 2H),
23 3.90 (s, 3H); ^{13}C NMR (101 MHz, DMSO) δ 178.84, 166.37, 160.71, 149.46, 141.88, 139.74,
24 139.44, 134.89, 134.70, 128.93, 127.59, 127.17, 127.04, 126.61, 115.96, 109.86, 108.68, 107.90,
25 56.73, 56.29; m/z MS (TOF ES⁺) $\text{C}_{24}\text{H}_{20}\text{NO}_4$ [MH]⁺ calcd 386.1; found 386.2; LC-MS t_{R} : 5.82.

26
27
28
29
30
31
32
33
34
35
36
37
38 **1-([1,1'-Biphenyl]-4-ylmethyl)-8-fluoro-5-hydroxy-4-oxo-1,4-dihydroquinoline-3-carboxylic**
39 **acid (7)**. Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-
40 carboxylate **(4a)** (102 mg, 0.24 mmol) was dispersed in 1 M NaOH (aq)/1,4-dioxane (1:1, 2mL) and
41 heated at 80 °C for 3.5 h, followed by stirring at rt overnight. After this time, complete conversion
42 to the acid had been achieved. The mixture was heated under reflux for a further 30 h, with no
43 appreciable progress noted. LiOH.H₂O (41 mg, 1.22 mmol, 5.1 eq) were added and reflux
44 continued overnight, followed by stirring at rt for a further week. After this time, the entire mixture
45 was transferred to a microwave vial, and LiOH.H₂O (5 eq) added. The vessel was sealed, and
46 heated at 160 °C for 1 h. LC-MS analysis after this time indicated complete conversion to the title
47 compound. The mixture was diluted with water (20 mL) and washed with Et₂O (20 mL), before
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 acidification with 2 M HCl (aq). The resultant precipitate was collected by filtration (vacuum), to
4
5 give 75 mg of yellow/brown solid. This was recrystallised from EtOAc, to give 49 mg of off-white
6
7 solid (53%). ¹H NMR (400 MHz, DMSO) δ 13.37 (s, 1H), 13.29 (s, 1H), 9.17 (s, 1H), 7.78–7.54
8
9 (m, 5H), 7.45 (dd, *J* = 7.6 Hz, 2H), 7.35 (dd, *J* = 7.3 Hz, 1H), 7.25 (d, *J* = 8.1 Hz, 2H), 6.87 (dd, *J* =
10
11 9.0, 3.2 Hz, 1H), 5.89 (d, *J* = 3.0 Hz, 2H); ¹³C NMR (101 MHz, DMSO) δ 180.38, 164.38, 157.74
12
13 (d, *J*_{CF} = 1.8 Hz), 153.29, 143.26 (d, *J*_{CF} = 240.5 Hz), 139.62, 139.47, 135.58 (d, *J*_{CF} = 1.6 Hz),
14
15 128.92, 128.47, 127.55, 127.05, 126.61, 126.42, 123.44 (d, *J*_{CF} = 24.7 Hz), 114.04, 111.99 (d, *J*_{CF} =
16
17 7.7 Hz), 107.97 (d, *J*_{CF} = 1.9 Hz), 60.38 (d, *J*_{CF} = 14.9 Hz); *m/z* MS (TOF ES⁺) C₂₃H₁₇FNO₄ [MH]⁺
18
19 calcd 390.1; found 390.1; LC-MS *t*_R: 5.93.
20
21

22
23 ***N*-Ethyl-5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (8a).**

24
25 The title compound was obtained through condensation of 2M ethylamine in THF with the acid
26
27 chloride intermediate described in general procedure E, to give 40 mg of white solid (37%). ¹H
28
29 NMR (400 MHz, CDCl₃) δ 9.77 (s, 1H), 8.80 (s, 1H), 7.35–7.26 (m, 1H), 7.08 (d, *J* = 8.3 Hz, 2H),
30
31 7.00 (ddd, *J* = 10.8, 9.0, 3.4 Hz, 1H), 6.87–6.79 (m, 2H), 5.52 (d, *J* = 2.9 Hz, 2H), 3.77 (s, 3H), 3.49
32
33 (qd, *J* = 7.3, 5.6 Hz, 2H), 1.26 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 175.71, 163.89,
34
35 159.90, 158.69 (dd, *J*_{CF} = 262.2, 2.7 Hz), 150.44, 147.81 (d, *J*_{CF} = 283.9 Hz), 129.35, 127.98,
36
37 127.19, 120.14 (d, *J*_{CF} = 11.5 Hz), 119.83, 114.60, 113.82, 111.97 (dd, *J*_{CF} = 24.4, 8.3 Hz), 61.00
38
39 (d, *J*_{CF} = 17.1 Hz), 55.44, 34.35, 14.98; *m/z* MS (TOF ES⁺) C₂₀H₁₈F₂N₂NaO₃ [MH]⁺ calcd 395.1;
40
41 found 395.1; LC-MS *t*_R: 5.70.
42
43
44

45
46 **5,8-Difluoro-1-(4-methoxybenzyl)-*N,N*-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide**
47
48 **(8b).** The title compound was obtained through coupling of dimethylamine hydrochloride with 5,8-
49
50 difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (**5a**), as described in
51
52 general procedure F. FCC purification (eluent MeOH/DCM 1:99 to 2:98) gave 112 mg of pale
53
54 yellow oil that solidified on standing to a yellow solid (quantitative yield). ¹H NMR (400 MHz,
55
56 CDCl₃) δ 7.92 (s, 1H), 7.23 (ddd, *J* = 13.6, 6.6, 2.8 Hz, 1H), 7.09 (d, *J* = 8.4 Hz, 2H), 6.91 (ddd, *J* =
57
58 10.5, 9.0, 3.3 Hz, 1H), 6.87 – 6.78 (m, 2H), 5.39 (d, *J* = 2.6 Hz, 2H), 3.75 (s, 3H), 3.08 (s, 3H), 3.03
59
60

(s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 171.80, 166.31, 159.75, 158.44 (dd, $J_{\text{CF}} = 260.5, 1.7$ Hz), 147.82 (dd, $J_{\text{CF}} = 246.0, 4.4$ Hz), 147.18, 130.60 (dd, $J_{\text{CF}} = 8.2, 2.8$ Hz), 127.98 (d, $J_{\text{CF}} = 1.4$ Hz), 127.52 (d, $J_{\text{CF}} = 1.0$ Hz), 121.17, 119.59 (d, $J_{\text{CF}} = 10.7$ Hz), 119.33 (d, $J_{\text{CF}} = 8.6$ Hz), 114.54, 111.08 (dd, $J_{\text{CF}} = 24.6, 8.2$ Hz), 60.01 (d, $J_{\text{CF}} = 17.2$ Hz), 55.38, 38.77, 35.61; m/z MS (TOF ES^+) $\text{C}_{20}\text{H}_{19}\text{F}_2\text{N}_2\text{O}_3$ $[\text{MH}]^+$ calcd 373.1; found 373.2; LC-MS t_{R} : 4.92.

5,8-Difluoro-1-(4-methoxybenzyl)-4-oxo-*N*-phenyl-1,4-dihydroquinoline-3-carboxamide

(8c). The title compound was obtained through condensation of aniline with the acid chloride intermediate described in general procedure E, to give 47 mg of white solid (39%). ^1H NMR (400 MHz, CDCl_3) δ 11.97 (s, 1H), 8.89 (s, 1H), 7.77 (dd, $J = 8.6, 1.0$ Hz, 2H), 7.41–7.28 (m, 3H), 7.16–7.00 (m, 4H), 6.90–6.80 (m, 2H), 5.56 (d, $J = 2.8$ Hz, 2H), 3.77 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 175.78, 162.07, 160.01, 158.73 (dd, $J_{\text{CF}} = 266.7, 4.2$ Hz), 150.79, 148.03 (dd, $J_{\text{CF}} = 247.2, 3.6$ Hz), 138.61, 130.27, 129.08, 128.09, 126.95, 124.22, 120.68, 120.36 (dd, $J_{\text{CF}} = 26.2, 10.7$ Hz), 119.71 (d, $J_{\text{CF}} = 7.4$ Hz), 114.69, 113.79, 112.37 (dd, $J_{\text{CF}} = 24.9, 8.2$ Hz), 61.24 (d, $J_{\text{CF}} = 17.5$ Hz), 55.45; m/z MS (TOF ES^+) $\text{C}_{24}\text{H}_{19}\text{F}_2\text{N}_2\text{O}_3$ $[\text{MH}]^+$ calcd 421.1; found 421.1; LC-MS t_{R} : 6.12.

***N*-Benzyl-5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide**

(8d). The title compound was obtained through condensation of benzylamine with the acid chloride intermediate described in general procedure E, to give 49 mg of white solid (39%). ^1H NMR (400 MHz, CDCl_3) δ 10.18 (t, $J = 5.4$ Hz, 1H), 8.83 (s, 1H), 7.47–7.19 (m, 7H), 7.08 (d, $J = 8.4$ Hz, 2H), 7.00 (ddd, $J = 10.8, 9.0, 3.4$ Hz, 1H), 6.91–6.76 (m, 2H), 5.52 (d, $J = 2.9$ Hz, 2H), 4.65 (d, $J = 5.8$ Hz, 2H), 3.77 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 175.69, 164.13, 159.93, 158.76 (dd, $J_{\text{CF}} = 244.7, 2.6$ Hz), 150.63, 147.88 (d, $J_{\text{CF}} = 263.1$ Hz), 138.62, 129.50 (d, $J_{\text{CF}} = 10.1$ Hz), 128.75, 128.00, 127.99, 127.34, 127.12 (d, $J_{\text{CF}} = 1.2$ Hz), 120.12 (dd, $J_{\text{CF}} = 25.8, 10.7$ Hz), 119.84 (d, $J_{\text{CF}} = 7.4$ Hz), 114.62, 113.64, 112.08 (dd, $J_{\text{CF}} = 24.6, 8.6$ Hz), 61.06 (d, $J_{\text{CF}} = 17.3$ Hz), 55.44, 43.61; m/z MS (TOF ES^+) $\text{C}_{25}\text{H}_{21}\text{F}_2\text{N}_2\text{O}_3$ $[\text{MH}]^+$ calcd 435.2; found 435.1; LC-MS t_{R} : 5.99.

5,8-Difluoro-1-(4-methoxybenzyl)-4-oxo-*N*-(piperidin-1-yl)-1,4-dihydroquinoline-3-carboxamide (8e). The title compound was obtained through coupling of 1-aminopiperidine with

1
2
3 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (**5a**), as described
4
5 in general procedure F. FCC purification (eluent MeOH/DCM 0:100 to 5:95), followed PLC
6
7 purification (MeOH/DCM 2:98, plate run 3 times) gave 77 mg of off-white solid (62%). ¹H NMR
8
9 (400 MHz, CDCl₃) δ 10.58 (s, 1H), 8.81 (s, 1H), 7.36–7.26 (m, 1H), 7.14–6.94 (m, 3H), 6.89–6.76
10
11 (m, 2H), 5.53 (d, *J* = 2.9 Hz, 2H), 3.77 (s, 3H), 3.09–2.68 (m, 4H), 1.88–1.65 (m, 4H), 1.47 (d, *J* =
12
13 5.2 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 175.34, 161.54, 159.92, 158.73 (d, *J*_{CF} = 257.5 Hz),
14
15 150.65, 147.95 (d, *J*_{CF} = 242.2 Hz), 128.66 (d, *J*_{CF} = 5.6 Hz), 127.97, 127.13, 120.05 (d, *J*_{CF} = 5.2
16
17 Hz), 119.76 (d, *J*_{CF} = 6.7 Hz), 114.61, 113.78, 112.07 (dd, *J*_{CF} = 24.7, 8.3 Hz), 61.08 (d, *J*_{CF} = 16.9
18
19 Hz), 57.18, 55.44, 25.25, 23.64; *m/z* MS (TOF ES⁺) C₂₃H₂₄F₂N₃O₃ [MH]⁺ calcd 428.2; found 428.2;
20
21 LC-MS *t*_R: 5.21.
22
23

24
25 **5,8-Difluoro-*N*-((1*S*,2*S*)-2-hydroxycyclohexyl)-1-(4-methoxybenzyl)-4-oxo-1,4-**
26
27 **dihydroquinoline-3-carboxamide (8f).** The title compound was obtained through coupling of
28
29 (*1S,2S*)-2-aminocyclohexanol hydrochloride with 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-
30
31 dihydroquinoline-3-carboxylic acid (**5a**), as described in general procedure F. FCC purification
32
33 (eluent EtOAc/PE 0:100 to 100:0) gave 148 mg of off-white solid (quantitative yield). ¹H NMR
34
35 (400 MHz, CDCl₃) δ 9.99 (d, *J* = 6.9 Hz, 1H), 8.80 (s, 1H), 7.39–7.17 (m, 1H), 7.14–6.94 (m, 3H),
36
37 6.93 – 6.73 (m, 2H), 5.52 (d, *J* = 2.7 Hz, 2H), 4.07 (s, 1H), 3.91 – 3.67 (m, 4H), 3.58–3.37 (m, 1H),
38
39 2.19–1.95 (m, 2H), 1.83–1.68 (m, 2H), 1.53–1.27 (m, 4H); ¹³C NMR (101 MHz, CDCl₃) δ 175.63,
40
41 165.92, 159.94, 156.41 (d, *J*_{CF} = 238.8 Hz), 150.80, 145.47 (d, *J*_{CF} = 255.7 Hz), 130.24 (dd, *J*_{CF} =
42
43 8.7, 1.9 Hz), 127.97, 127.03, 120.26 (dd, *J*_{CF} = 25.4, 10.5 Hz), 119.71 (d, *J*_{CF} = 7.5 Hz), 114.64,
44
45 113.06, 112.25 (dd, *J*_{CF} = 24.9, 8.2 Hz), 76.11, 61.14 (d, *J*_{CF} = 17.1 Hz), 55.97, 55.44, 38.75, 34.48,
46
47 31.49, 24.83, 24.10; *m/z* MS (TOF ES⁺) C₂₄H₂₅F₂N₂O₄ [MH]⁺ calcd 443.2; found 443.2; LC-MS *t*_R:
48
49 5.32; [α]_D²⁴ = + 498° (0.0105, DCM).
50
51
52

53
54 **5,8-Difluoro-1-(4-methoxybenzyl)-3-(morpholine-4-carbonyl)quinolin-4(1*H*)-one (8g).** 5,8-
55
56 difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (**5a**) (100 mg, 0.29
57
58 mmol) was dispersed in dry DCM (1 mL) under an atmosphere of N₂ and cooled to 0 °C, over an
59
60

ice bath. To this was added oxalyl chloride (0.028 mL, 0.32 mmol, 1.1 eq) and DMF (1 drop) and the mixture stirred on the ice bath for 10 min, before warming to rt and stirring for a further 20 min. TLC analysis (EtOAc) indicated starting material had been consumed. Morpholine (0.053 mL, 0.61 mmol, 2.1 eq) was added, and the mixture stirred for 10 min at rt, before diluting with DCM (20 mL) and washing with 0.5 M HCl_(aq) (20 mL) and sat. NaHCO_{3(aq)} (20 mL). After concentration of the organic layer under reduced pressure, the crude was further purified by FCC (eluent EtOAc 10:90 to 100:0) to give 100 mg of colourless glassy solid (83%). ¹H NMR (400 MHz, DMSO) δ 8.35 (s, 1H), 7.66–7.49 (m, 1H), 7.22–7.00 (m, 3H), 6.95–6.80 (m, 2H), 5.52 (d, *J* = 3.2 Hz, 2H), 3.70 (s, 3H), 3.67–3.53 (m, 6H), 3.40–3.19 (m, 2H); ¹³C NMR (101 MHz, DMSO) δ 170.90, 164.13, 158.74, 158.71 (d, *J*_{CF} = 235.1 Hz), 146.88, 146.86 (d, *J*_{CF} = 260.9 Hz), 130.37 (d, *J*_{CF} = 3.4 Hz), 128.82, 127.30, 120.50 (d, *J*_{CF} = 6.2 Hz), 119.91 (d, *J*_{CF} = 2.4 Hz), 114.15, 111.51, 110.76 (dd, *J*_{CF} = 22.5/9.0 Hz), 66.47, 66.05, 58.74 (d, *J*_{CF} = 15.3 Hz), 55.04, 47.10, 41.99; *m/z* MS (TOF ES⁻) C₂₂H₂₁F₂N₂O₄ [M+H]⁺ calcd 415.2; found 415.2; LC-MS *t*_R: 5.27.

5,8-Difluoro-1-(4-methoxybenzyl)-3-(piperidine-1-carbonyl)quinolin-4(1*H*)-one (8h). The title compound was obtained through condensation of piperidine with the acid chloride intermediate described in general procedure E, to give 45 mg of off-white semisolid (38%). ¹H NMR (400 MHz, CDCl₃) δ 7.88 (s, 1H), 7.26–7.16 (m, 1H), 7.09 (d, *J* = 8.5 Hz, 2H), 6.91 (ddd, *J* = 10.5, 9.0, 3.3 Hz, 1H), 6.87 – 6.80 (m, 2H), 5.39 (d, *J* = 2.5 Hz, 2H), 3.77 (s, 3H), 3.69 (s, 2H), 3.36 (s, 2H), 1.83–1.43 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 171.91, 164.51, 159.77, 158.51 (dd, *J*_{CF} = 261.8, 2.9 Hz), 147.84 (dd, *J*_{CF} = 246.0, 4.4 Hz), 146.82, 130.66 (dd, *J*_{CF} = 8.1, 2.8 Hz), 128.00, 127.99, 127.62, 121.38, 119.41 (dd, *J*_{CF} = 25.6, 10.7 Hz), 114.56, 111.24, 111.00 (dd, *J*_{CF} = 24.6, 8.2 Hz), 60.01 (d, *J*_{CF} = 17.2 Hz), 55.41, 48.75, 43.45, 26.64, 25.69, 24.62; *m/z* MS (TOF ES⁺) C₂₃H₂₃F₂N₂O₃ [MH]⁺ calcd 413.2; found 413.2; LC-MS *t*_R: 5.55.

5,8-Difluoro-*N*-hydroxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (8i). The title compound was obtained through condensation of hydroxylamine hydrochloride with the acid chloride intermediate described in general procedure E. The crude product was dissolved in

1
2
3 the minimum amount of MeOH, before addition of EtOAc, causing precipitation of a pink solid to
4 occur. This was collected by filtration (vacuum) to give 19 mg of the desired compound (18%, >
5 90% pure). ^1H NMR (400 MHz, DMSO) δ 11.46 (s, 1H), 9.28 (s, 1H), 8.89 (s, 1H), 7.75 – 7.54 (m,
6 1H), 7.33 – 7.18 (m, 1H), 7.07 (d, $J = 8.5$ Hz, 2H), 6.89 (d, $J = 8.7$ Hz, 2H), 5.71 (d, $J = 3.1$ Hz,
7 2H), 3.70 (s, 3H); ^{13}C NMR (101 MHz, DMSO) δ 173.59, 161.53, 160.37 (d, $J_{CF} = 250.8$ Hz),
8 158.80, 150.21, 147.49 (d, $J_{CF} = 244.2$ Hz), 129.96 (dd, $J_{CF} = 6.6, 1.7$ Hz), 128.48, 127.45, 120.54
9 (dd, $J_{CF} = 26.3, 9.9$ Hz), 118.58 (d, $J_{CF} = 7.9$ Hz), 114.19, 112.56, 112.04 (dd, $J_{CF} = 23.3, 8.1$ Hz),
10 59.55 (d, $J_{CF} = 16.2$ Hz), 55.05; m/z MS (TOF ES⁺) $\text{C}_{18}\text{H}_{15}\text{F}_2\text{N}_2\text{O}_4$ $[\text{MH}]^+$ calcd 361.1; found 361.1;
11 LC-MS t_{R} : 5.51.

22
23 **5,8-Difluoro-1-(4-methoxybenzyl)-*N*-(methylsulfonyl)-4-oxo-1,4-dihydroquinoline-3-**
24 **carboxamide (9).** 5,8-Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic
25 acid (**5a**) (100 mg, 0.29 mmol) was dispersed in dry DCM (1 mL) under an atmosphere of N_2 and
26 cooled to 0 °C, over an ice bath. To this were added oxalyl chloride (0.028 mL, 0.32 mmol, 1.1 eq)
27 and DMF (1 drop) and the mixture stirred on the ice bath for 10 min, before stirring at rt for 30 min.
28 Oxalyl chloride (0.2 eq) was added, and stirring continued at rt for 10 min. The mixture was
29 concentrated under reduced pressure, before redissolving in dry DCM (1 mL) and
30 methanesulfonamide (28 mg, 0.29 mmol, 1 eq). The mixture was cooled over an ice bath, under an
31 atmosphere of N_2 , before adding TEA (0.121 mL, 0.87 mmol, 3 eq). The mixture was warmed to rt,
32 and left to stir overnight, before diluting with DCM (20 mL) and washing with 1 M $\text{HCl}_{(\text{aq})}$ (20
33 mL). The organic layer was concentrated and the residue purified by FCC (eluent EtOAc/PE 0:100
34 to 100:0) to give 48 mg of white crystalline solid (39%) ^1H NMR (400 MHz, CDCl_3) δ 12.61 (s,
35 1H), 8.72 (s, 1H), 7.39 (ddd, $J = 13.5, 9.0, 4.3$ Hz, 1H), 7.18–7.01 (m, 3H), 6.95–6.77 (m, 2H), 5.56
36 (d, $J = 2.8$ Hz, 2H), 3.79 (s, 3H), 3.36 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 175.36, 163.08,
37 160.28, 159.30 (d, $J_{CF} = 240.6$ Hz), 151.09, 147.11 (d, $J_{CF} = 278.8$ Hz), 129.65, 128.35, 126.04,
38 121.39 (dd, $J_{CF} = 13.6, 10.8$ Hz), 121.15, 114.89, 113.63 (d, $J_{CF} = 12.6$ Hz), 111.19, 61.62 (d, $J_{CF} =$
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 17.6 Hz), 55.49, 41.97; *m/z* MS (TOF ES⁺) C₁₉H₁₆F₂N₂NaO₅S [M+Na]⁺ calcd 445.1; found 445.1;
4
5 LC-MS *t*_R: 5.32.

7 **5,8-Difluoro-1-(4-methoxybenzyl)-*N*-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide**

9
10 **(10a)**. Ethyl 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate **(3a)** (100
11 mg, 0.27 mmol) was stirred in a mixture of EtOH/40% MeNH₂ (aq) (1:1, 2 mL) at rt overnight. TLC
12 analysis (EtOAc/DCM 1:1) indicated complete conversion had taken place. The mixture was
13 poured on to ice water, and the resulting precipitate collected by filtration (vacuum), before drying
14 to give 80 mg of pale yellow solid (83%). ¹H NMR (400 MHz, CDCl₃) δ 9.72 (d, *J* = 3.7 Hz, 1H),
15 8.80 (s, 1H), 7.38–7.19 (m, 1H), 7.07 (d, *J* = 8.4 Hz, 2H), 7.00 (ddd, *J* = 10.8, 9.1, 3.3 Hz, 1H), 6.83
16 (d, *J* = 8.7 Hz, 2H), 5.52 (d, *J* = 2.7 Hz, 2H), 3.77 (s, 3H), 2.99 (d, *J* = 4.9 Hz, 3H); ¹³C NMR (101
17 MHz, CDCl₃) δ 175.64, 164.76, 159.91, 158.68 (dd, *J*_{CF} = 262.7, 2.8 Hz), 150.35, 147.88 (d, *J*_{CF} =
18 259.7 Hz), 130.33 (dd, *J*_{CF} = 8.0, 2.4 Hz), 127.98 (d, *J*_{CF} = 1.5 Hz), 127.18 (d, *J*_{CF} = 1.0 Hz), 120.03
19 (dd, *J*_{CF} = 25.7, 11.0 Hz), 119.86 (d, *J*_{CF} = 7.4 Hz), 114.61, 113.79, 111.98 (dd, *J*_{CF} = 24.8, 8.2 Hz),
20 60.98 (d, *J*_{CF} = 17.2 Hz), 55.43, 26.10; *m/z* MS (TOF ES⁺) C₁₉H₁₆F₂N₂NaO₃ [M+Na]⁺ calcd 381.1;
21 found 381.2; LC-MS *t*_R: 5.16.

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36 **5,8-Difluoro-*N*-(2-hydroxyethyl)-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-**
37
38 **carboxamide (10b)**. Ethyl 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-
39 carboxylate **(3a)** (100 mg, 0.27 mmol) was stirred in a mixture of EtOH/ethanolamine (2:1, 3 mL)
40 at rt for 3.75 h. TLC analysis (EtOAc) indicated only partial progression, so EtOH (2 mL) was
41 added to aid further dissolution. After overnight stirring, complete conversion had taken place. The
42 mixture was poured on to ice/2 M HCl (aq), and the resulting precipitate collected by filtration
43 (vacuum), with washings of water. After drying, 91 mg of yellow solid was obtained (88%). ¹H
44 NMR (400 MHz, CDCl₃) δ 10.17 (s, 1H), 8.79 (s, 1H), 7.31 (ddd, *J* = 13.6, 9.0, 4.3 Hz, 1H), 7.14–
45 6.96 (m, 3H), 6.91–6.78 (m, 2H), 5.52 (d, *J* = 2.8 Hz, 2H), 3.83 (s, 2H), 3.77 (s, 3H), 3.63 (dd, *J* =
46 10.0, 5.6 Hz, 2H), 3.37 (d, *J* = 4.5 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 175.60, 165.93, 159.96,
47 157.29 (d, *J*_{CF} = 273.1 Hz), 150.58, 147.96 (d, *J*_{CF} = 245.2 Hz), 130.28 (d, *J*_{CF} = 8.5 Hz), 127.98 (d,
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 $J_{CF} = 1.5$ Hz), 127.02 (d, $J_{CF} = 1.1$ Hz), 120.25 (dd, $J_{CF} = 25.6, 11.0$ Hz), 119.74 (d, $J_{CF} = 7.7$ Hz),
4
5 114.65, 113.21, 112.25 (dd, $J_{CF} = 24.7, 8.1$ Hz), 63.43, 61.11 (d, $J_{CF} = 17.1$ Hz), 55.44, 43.16; m/z
6
7 MS (TOF ES⁺) C₂₀H₁₉F₂N₂O₄ [MH]⁺ calcd 389.1; found 389.2; LC-MS t_R : 4.90.

9
10 **5,8-Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (11).** Ethyl
11
12 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (**3a**) (520 mg, 1.39
13
14 mmol) was dispersed in 28-30% NH₃ (aq)/EtOH (1:1, 8 mL) and stirred at rt in a closed vessel for 60
15
16 h. TLC analysis (EtOAc) indicated complete conversion had taken place. The mixture was diluted
17
18 with water and stirred for 10 min, before collecting the resulting precipitate by filtration (vacuum),
19
20 and drying to give 423 mg (88%) of white solid. ¹H NMR (400 MHz, CDCl₃) δ 9.50 (s, 1H), 8.79
21
22 (s, 1H), 7.30 (ddd, $J = 13.6/9.0/4.3$ Hz, 1H), 7.08 (d, $J = 8.2$ Hz, 2H), 7.02 (ddd, $J = 10.7/9.0/3.4$
23
24 Hz, 1H), 6.88 – 6.80 (m, 2H), 5.75 (s, 1H), 5.51 (d, $J = 2.9$ Hz, 2H), 3.77 (s, 3H); ¹³C NMR (101
25
26 MHz, CDCl₃) δ 175.41, 165.80, 159.92, 158.69 (d, $J_{CF} = 262.4$ Hz), 151.03, 147.98 (d, $J_{CF} = 246.8$
27
28 Hz), 130.37 (dd, $J_{CF} = 8.6/2.9$ Hz), 127.92, 127.90, 127.08, 120.26 (dd, $J_{CF} = 25.8/10.7$ Hz), 119.87
29
30 (d, $J_{CF} = 7.2$ Hz), 114.62, 113.42, 112.30 (dd, $J_{CF} = 24.8/8.4$ Hz), 61.10 (d, $J_{CF} = 16.9$ Hz), 55.44;
31
32 m/z MS (TOF ES⁺) C₁₈H₁₄F₂N₂NaO₃ [M+Na]⁺ calcd 367.3; found 367.1; LC-MS t_R : 5.38.

33
34
35
36 **5,8-Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carbonitrile (12).** 5,8-
37
38 Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (**11**) (104 mg, 0.30
39
40 mmol) was stirred in MeCN/H₂O/MeOH (3:3:1, 7 mL) at rt, before adding PdCl₂ (20 mg, 0.12
41
42 mmol, 0.4 eq). The mixture was stirred at rt for 2 h, before adding THF (2 mL) and continuing
43
44 stirring at rt overnight. TLC analysis (EtOAc) indicated partial reaction progression, so stirring was
45
46 continued at 50 °C for a further overnight period, before adding in PdCl₂ (0.1 eq) and continuing
47
48 stirring at 50 °C for a final overnight period. After this, organic solvents were removed under
49
50 reduced pressure, and the residue diluted with water (20 mL), before extraction with DCM (3 x 20
51
52 mL). The combined organic extracts were washed with brine (30 mL), before concentration under
53
54 reduced pressure. The crude product was further purified by FCC (eluent EtOAc/PE 0:100 to 100:0)
55
56 to give 34 mg of off-white solid (35%). ¹H NMR (400 MHz, CDCl₃) δ 7.94 (s, 1H), 7.35 (ddd, $J =$
57
58
59
60

1
2
3 13.7, 9.1, 4.4 Hz, 1H), 7.12 (d, $J = 8.4$ Hz, 2H), 7.05 (ddd, $J = 10.0, 9.1, 3.4$ Hz, 1H), 6.96–6.82 (m,
4 2H), 5.44 (d, $J = 2.9$ Hz, 2H), 3.81 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 172.03, 160.35, 160.02
5
6 (dd, $J_{\text{CF}} = 257.5, 6.9$ Hz), 150.26, 147.99 (dd, $J_{\text{CF}} = 247.6, 4.3$ Hz), 130.12 (dd, $J_{\text{CF}} = 6.7, 3.5$ Hz),
7
8 128.58, 125.91, 121.20 (dd, $J_{\text{CF}} = 26.0, 10.4$ Hz), 118.47 (d, $J_{\text{CF}} = 8.5$ Hz), 115.01, 114.68, 113.24
9
10 (dd, $J_{\text{CF}} = 24.0, 8.4$ Hz), 98.65, 60.87 (d, $J_{\text{CF}} = 18.3$ Hz), 55.52; m/z MS (TOF ES^+)
11
12 $\text{C}_{18}\text{H}_{12}\text{F}_2\text{N}_2\text{NaO}_2$ [$\text{M}+\text{Na}$] $^+$ calcd 349.1; found 349.1; LC-MS t_{R} : 5.20.

13
14
15
16 **5,8-Difluoro-1-(4-methoxybenzyl)-3-(1H-tetrazol-5-yl)quinolin-4(1H)-one (13).** 5,8-Difluoro-
17
18 1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carbonitrile (**12**) (34 mg, 0.20 mmol), NaN_3
19
20 (20 mg, 0.31 mmol, 3 eq) and triethylammonium chloride (43 mg, 0.31 mmol, 3eq) were heated
21
22 with stirring in toluene (5 mL) at 100 °C overnight. TLC analysis (EtOAc) indicated no progress, so
23
24 further triethylammonium chloride (143 mg, 10 eq) and NaN_3 (67 mg, 10 eq) were added, and
25
26 heating continued under reflux for a further overnight period. TLC analysis indicated almost
27
28 complete conversion, so heating under reflux was continued for a further 7 h, then reduced to 70 °C
29
30 over the weekend. The mixture was cooled, then diluted with Et_2O (10 mL) and extracted with
31
32 water (2 x 10 mL). The aqueous layer was washed with Et_2O (10 mL), before acidifying with 2M
33
34 $\text{HCl}_{(\text{aq})}$ and extracting with EtOAc (2 x 10 mL). Concentration of the EtOAc layers followed by
35
36 PLC purification (MeOH/DCM 5:95, plate run twice) gave 14 mg of yellow solid (38%). ^1H NMR
37
38 (400 MHz, CDCl_3) δ 14.22 (s, 1H), 9.00 (s, 1H), 7.40 (ddd, $J = 13.6, 9.0, 4.3$ Hz, 1H), 7.20–7.01
39
40 (m, 3H), 6.96–6.72 (m, 2H), 5.61 (d, $J = 2.4$ Hz, 2H), 3.78 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ
41
42 176.71, 160.18, 158.50 (dd, $J_{\text{CF}} = 266.5, 3.1$ Hz), 150.66, 148.30 (d, $J_{\text{CF}} = 271.9$ Hz), 146.61,
43
44 130.12 (d, $J_{\text{CF}} = 11.1$ Hz), 128.13, 126.55, 120.80 (dd, $J_{\text{CF}} = 26.1, 10.9$ Hz), 118.73 (d, $J_{\text{CF}} = 8.7$
45
46 Hz), 114.83, 113.01 (dd, $J_{\text{CF}} = 23.9, 7.6$ Hz), 106.86, 61.34 (d, $J_{\text{CF}} = 17.8$ Hz), 55.48; m/z MS (TOF
47
48 ES^-) $\text{C}_{18}\text{H}_{12}\text{F}_2\text{N}_5\text{O}_2$ [$\text{M}-\text{H}$] $^-$ calcd 368.1; found 368.0; LC-MS t_{R} : 5.10.

49
50
51
52 **N-Acetyl-5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (14).**
53
54 5,8-Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (**11**) (50 mg, 0.15
55
56 mmol) was dissolved in pyridine (1 mL), before adding Ac_2O (0.021 mL, 0.22 mmol, 1.5 eq) and
57
58
59
60

1
2
3 stirring at rt overnight. TLC analysis (EtOAc) indicated no progress, so Ac₂O (1 mL) and DCM (1
4 mL) were added, and stirring continued at rt overnight. The temperature was then increased to 100
5 °C, and after 2 d the starting material had disappeared. The mixture was cooled, diluted with water,
6 and stirred for 30 min at rt. The resulting precipitate was collected by filtration (vacuum) and
7 washed with water and PE. The crude solid was further purified by FCC (eluent EtOAc/PE 0:100 to
8 100:0) to give 37 mg of off-white solid (64%). ¹H NMR (400 MHz, CDCl₃) δ 12.27 (s, 1H), 8.77 (s,
9 1H), 7.36 (ddd, *J* = 13.5, 9.0, 4.3 Hz, 1H), 7.16–7.01 (m, 3H), 6.95–6.80 (m, 2H), 5.55 (d, *J* = 2.8
10 Hz, 2H), 3.78 (s, 3H), 2.46 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 175.41, 171.69, 162.89, 160.16,
11 158.71 (dd, *J*_{CF} = 264.1, 3.1 Hz), 151.64, 147.98 (d, *J*_{CF} = 247.4 Hz), 130.10 (dd, *J*_{CF} = 9.3, 2.5 Hz),
12 128.18, 126.45, 120.95 (dd, *J*_{CF} = 26.0, 10.5 Hz), 119.72 (d, *J*_{CF} = 7.7 Hz), 114.80, 113.14 (dd, *J*_{CF}
13 = 25.0, 8.4 Hz), 112.28, 61.45 (d, *J*_{CF} = 17.5 Hz), 55.47, 26.39; *m/z* MS (TOF ES⁺)
14 C₂₀H₁₆F₂N₂NaO₄ [M+Na]⁺ calcd 409.1; found 409.1; LC-MS *t*_R: 5.26.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Ethyl 1-([1,1'-biphenyl]-2-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate
(**15a**). Ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (**2a**) (500 mg, 1.97 mmol), was
alkylated with 2-(bromomethyl)biphenyl, according to general procedure C. The resulting crude
product was further purified by FCC (eluent EtOAc/PE 0:100 to 20:80) to give 480 mg (73%) of
pale yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.19 (s, 1H), 7.58–7.21 (m, 8H), 7.16 (ddd, *J* =
13.5/9.0/4.3 Hz, 1H), 7.02–6.83 (m, 2H), 5.42 (d, *J* = 2.7 Hz, 2H), 4.35 (q, *J* = 7.1 Hz, 2H), 1.37 (t,
J = 7.1 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 172.35, 164.99, 158.52 (dd, *J*_{CF} = 263.1/2.7 Hz),
151.17, 147.66 (dd, *J*_{CF} = 246.9/4.3 Hz), 141.06, 139.89, 133.07 (d, *J*_{CF} = 2.1 Hz), 130.75, 130.24
(d, *J*_{CF} = 5.7 Hz), 128.82, 128.78, 128.32, 128.23, 127.90, 125.61, 120.52 (d, *J*_{CF} = 7.7 Hz), 119.83
(dd, *J*_{CF} = 25.6/10.5 Hz), 113.04, 112.13 (dd, *J*_{CF} = 24.7/8.1 Hz), 61.22, 59.55 (d, *J*_{CF} = 16.9 Hz),
14.48; *m/z* MS (TOF ES⁺) C₂₅H₂₀F₂NO₃ [M+H]⁺ calcd 420.1; found 420.2; LC-MS *t*_R: 6.06.

Ethyl 1-([1,1'-biphenyl]-3-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate
(**15b**). Ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (**2a**) (500 mg, 1.97 mmol), was
alkylated with 3-phenylbenzyl bromide, according to general procedure C. The resulting crude

product was further purified by FCC (eluent EtOAc/PE 0:100 to 20:80) to give 619 mg (75%) of pale yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 8.46 (s, 1H), 7.58–7.47 (m, 3H), 7.47–7.31 (m, 5H), 7.29–7.17 (m, 1H), 7.07 (d, $J = 7.7$ Hz, 1H), 6.96 (ddd, $J = 10.0, 9.3, 3.4$ Hz, 1H), 5.56 (d, $J = 2.9$ Hz, 2H), 4.39 (q, $J = 7.1$ Hz, 2H), 1.40 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 172.48, 165.17, 158.68 (dd, $J_{\text{CF}} = 263.2/2.6$ Hz), 151.38, 147.76 (dd, $J_{\text{CF}} = 246.5/4.5$ Hz), 142.40, 140.39, 136.04 (d, $J_{\text{CF}} = 1.4$ Hz), 130.11 (d, $J_{\text{CF}} = 10.7$ Hz), 129.74, 129.06, 127.91, 127.48, 127.26, 124.92, 124.80, 120.65 (d, $J_{\text{CF}} = 7.5$ Hz), 120.07 (dd, $J_{\text{CF}} = 25.5/10.7$ Hz), 113.26, 112.40 (dd, $J_{\text{CF}} = 24.7/8.3$ Hz), 61.39, 61.05 (d, $J_{\text{CF}} = 16.9$ Hz), 14.50; m/z MS (TOF ES $^+$) $\text{C}_{25}\text{H}_{20}\text{F}_2\text{NO}_3$ $[\text{MH}]^+$ calcd 420.1; found 420.2; LC-MS t_{R} : 6.09.

1-([1,1'-Biphenyl]-2-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (16a). Ethyl 1-([1,1'-biphenyl]-2-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (**15a**) (100 mg, 0.24 mmol) was dispersed in 1,4-dioxane/2 M HCl (aq) (1:1, 2 mL) and heated at 80 $^\circ\text{C}$ for 5 h. TLC analysis (EtOAc) indicated complete hydrolysis had taken place. The mixture was cooled to rt, before diluting with water (20 mL) and extracting with DCM (3 \times 20 mL). Concentration of the combined organic layers gave 90 mg of pale yellow solid (96%). ^1H NMR (400 MHz, CDCl_3) δ 14.32 (s, 1H), 8.48 (s, 1H), 7.50–7.27 (m, 7H), 7.23–7.16 (m, 2H), 7.09 (ddd, $J = 10.2/9.1/3.4$ Hz, 1H), 6.94 (d, $J = 7.7$ Hz, 1H), 5.58 (d, $J = 3.0$ Hz, 2H); ^{13}C NMR (101 MHz, CDCl_3) δ 177.71, 165.83, 158.24 (dd, $J_{\text{CF}} = 265.1/2.7$ Hz), 151.52, 147.94 (dd, $J_{\text{CF}} = 248.7/4.5$ Hz), 141.25, 139.69, 132.10 (d, $J_{\text{CF}} = 2.1$ Hz), 131.07, 131.03, 129.02, 128.87, 128.59, 128.33, 128.13, 126.25 (d, $J_{\text{CF}} = 1.6$ Hz), 121.35 (dd, $J_{\text{CF}} = 25.6/10.8$ Hz), 118.33 (d, $J_{\text{CF}} = 9.2$ Hz), 113.19 (dd, $J_{\text{CF}} = 23.98.0$ Hz), 110.22, 60.87 (d, $J_{\text{CF}} = 16.9$ Hz); m/z MS (TOF ES $^+$) $\text{C}_{23}\text{H}_{16}\text{F}_2\text{NO}_3$ $[\text{MH}]^+$ calcd 392.1; found 392.1; LC-MS t_{R} : 6.00.

1-([1,1'-Biphenyl]-3-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (16b). Ethyl 1-([1,1'-biphenyl]-3-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (**15b**) (101 mg, 0.24 mmol) was dispersed in 1,4-dioxane/0.2 M HCl (aq) (1:1, 2 mL) and heated at 60 $^\circ\text{C}$ for 3 h. TLC analysis (EtOAc/DCM 1:1) indicated no progress. Heating was continued at 80

1
2
3 °C for a further 1.25 h, before adding in 2M HCl_(aq) (0.15 mL). Heating was continued at 80 °C for
4
5 a further 1.75 h, followed by rt stirring overnight. After a final 6 h of heating under reflux, the
6
7 mixture was cooled, diluted with water, and the resulting precipitate collected by filtration
8
9 (vacuum), with washings of water and PE. After drying, 85 mg of pale yellow solid was obtained
10
11 (91%). ¹H NMR (400 MHz, DMSO) δ 14.78 (s, 1H), 9.18 (s, 1H), 7.78 (ddd, *J* = 13.8/9.1/4.4 Hz,
12
13 1H), 7.68–7.56 (m, 3H), 7.54 (s, 1H), 7.50–7.31 (m, 5H), 7.09 (d, *J* = 7.7 Hz, 1H), 5.94 (d, *J* = 3.9
14
15 Hz, 2H); ¹³C NMR (101 MHz, DMSO) δ 177.06, 165.24, 157.16 (dd, *J*_{CF} = 261.6/2.3 Hz), 152.57,
16
17 147.26 (dd, *J*_{CF} = 232.5/7.8 Hz), 140.62, 139.60, 137.16 (d, *J*_{CF} = 2.4 Hz), 130.32 (dd, *J*_{CF} =
18
19 12.0/2.8 Hz), 129.46, 128.95, 127.67, 126.73, 126.18, 124.61, 124.33, 121.88 (dd, *J*_{CF} = 25.7/10.3
20
21 Hz), 117.55 (d, *J*_{CF} = 10.0 Hz), 113.26 (dd, *J*_{CF} = 23.2/9.0 Hz), 109.40, 60.70 (d, *J*_{CF} = 15.3 Hz);
22
23 *m/z* MS (TOF ES⁺) C₂₃H₁₆F₂NO₃ [MH]⁺ calcd 392.1; found 392.1; LC-MS *t*_R: 6.05.
24
25

26
27 ***tert*-Butyl prop-2-yn-1-ylcarbamate (18)**. Propargylamine (**17**) (5.126 g, 93.06 mmol) was
28
29 dissolved in water (100 mL) with stirring. To this was added Boc₂O (21.325 g, 97.71 mmol, 1.05
30
31 eq), and the mixture was stirred at rt overnight. TLC analysis (MeOH/DCM 1:9) indicated complete
32
33 conversion. The mixture was extracted with DCM (3 × 30 mL), and the combined organic extracts
34
35 washed with water (50 mL). Concentration of the organic layers gave 13.902 g of pale yellow oil,
36
37 which rapidly crystallised to off-white crystals (96%). ¹H NMR (400 MHz, CDCl₃) δ 4.70 (s, 1H),
38
39 3.92 (d, *J* = 3.0 Hz, 2H), 2.21 (t, *J* = 2.5 Hz, 1H), 1.45 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ
40
41 146.90, 85.32, 80.21, 71.38, 28.48, 27.57.
42
43

44
45 ***tert*-Butyl (3-(4-(hydroxymethyl)phenyl)prop-2-yn-1-yl)carbamate (19)**.³⁹ 4-Iodobenzyl
46
47 alcohol (2.02 g, 8.55 mmol), *tert*-butyl prop-2-yn-1-ylcarbamate (**18**) (1.724 g, 11.11 mmol, 1.3 eq)
48
49 and TEA (3.573 mL, 25.64 mmol, 3 eq) were placed in a flask in dry THF (20 mL), and degassed
50
51 by sonication (10 min). CuI (82 mg, 0.43 mmol, 0.05 eq) and PdCl₂(PPh₃)₂ (302 mg, 0.43 mmol,
52
53 0.05 eq) were added, and the mixture stirred at rt overnight. TLC analysis (EtOAc/PE 3:7) indicated
54
55 complete depletion of the alkyne. The mixture was diluted with EtOAc (100 mL), before filtering
56
57 through a bed of celite (vacuum). The filtrate was washed with water (2 x 50 mL) and brine (50
58
59
60

mL), before concentration and further purification by FCC (eluent EtOAc/PE 0:100 to 30:70) to give 933 mg of light brown solid (42%). ^1H NMR (400 MHz, CDCl_3) δ 7.40 (d, $J = 8.2$ Hz, 2H), 7.30 (d, $J = 8.4$ Hz, 2H), 4.77 (s, 1H), 4.69 (d, $J = 5.5$ Hz, 2H), 4.15 (d, $J = 4.7$ Hz, 2H), 1.76 (t, $J = 5.8$ Hz, 1H), 1.47 (s, 9H); ^{13}C NMR (101 MHz, CDCl_3) δ 150.57, 141.26, 132.02, 126.89, 122.08, 85.55, 83.07, 71.61, 65.05, 31.35, 28.52; m/z MS (TOF ES^+) $\text{C}_{11}\text{H}_{12}\text{NO}_3$ $[\text{M}-^t\text{Bu}+2\text{H}]^+$ calcd 206.1; found 206.2; LC-MS t_{R} : 5.54.

***tert*-Butyl (3-(4-(bromomethyl)phenyl)prop-2-yn-1-yl)carbamate (20).** *tert*-Butyl (3-(4-(hydroxymethyl)phenyl)prop-2-yn-1-yl)carbamate (**19**) (880 mg, 3.37 mmol) and CBr_4 (1.227 g, 3.70 mmol, 1.1 eq) were dissolved in DCM (20 mL), before cooling over an ice bath. PPh_3 (970 mg, 3.70 mmol, 1.1 eq) was added, and the mixture allowed to warm to rt with stirring. After 1.5 h of stirring at rt, TLC analysis (EtOAc/PE 3:7) indicated good progression. PPh_3 (0.5 eq) was added, and stirring continued overnight. The mixture was concentrated under reduced pressure, and the crude residue further purified by FCC (eluent EtOAc/PE 0:100 to 30:70) to give 595 mg of shiny off-white solid (55%). ^1H NMR (400 MHz, CDCl_3) δ 7.40–7.34 (m, 2H), 7.34–7.27 (m, 2H), 4.75 (s, 1H), 4.46 (s, 2H), 4.14 (d, $J = 4.7$ Hz, 2H), 1.46 (s, 9H); ^{13}C NMR (101 MHz, CDCl_3) δ 155.40, 137.97, 132.16, 129.08, 122.98, 86.40, 82.68, 79.62, 32.96, 31.31, 28.46; m/z MS (TOF ES^+) $\text{C}_{11}\text{H}_{11}\text{BrNO}_2$ $[\text{M}-^t\text{Bu}+2\text{H}]^+$ calcd 268.0; found 268.0; LC-MS t_{R} : 6.29.

Ethyl 1-(4-(3-((*tert*-butoxycarbonyl)amino)prop-1-yn-1-yl)benzyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (21). Ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (**2a**) (199 mg, 0.79 mmol), was alkylated with *tert*-butyl (3-(4-(bromomethyl)phenyl)prop-2-yn-1-yl)carbamate (**20**), according to general procedure C. The resulting crude product was further purified by FCC (eluent EtOAc/PE 5:95 to 100:0) to give 392 mg (67%) of yellow solid ^1H NMR (400 MHz, CDCl_3) δ 8.39 (s, 1H), 7.38 (d, $J = 8.3$ Hz, 2H), 7.22 (ddd, $J = 13.5/9.0/4.3$ Hz, 1H), 7.05 (d, $J = 8.1$ Hz, 2H), 6.96 (ddd, $J = 10.3/9.1/3.4$ Hz, 1H), 5.47 (d, $J = 2.8$ Hz, 2H), 4.74 (s, 1H), 4.39 (q, $J = 7.1$ Hz, 2H), 4.13 (d, $J = 4.5$ Hz, 2H), 1.46 (s, 9H), 1.40 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 172.42, 165.20, 158.68 (d, $J_{\text{CF}} = 265.5$ Hz),

1
2
3 155.40, 151.31, 147.68 (d, $J_{CF} = 243.2$ Hz), 135.53 (d, $J_{CF} = 1.3$ Hz), 132.55, 129.99, 126.07,
4
5 123.28, 120.66 (d, $J_{CF} = 7.8$ Hz), 120.06 (dd, $J_{CF} = 25.5/10.5$ Hz), 113.40, 112.49 (d, $J_{CF} = 33.3$
6
7 Hz), 86.70, 82.33, 80.26, 61.46, 60.80 (d, $J_{CF} = 17.0$ Hz), 31.30, 28.50, 14.51; m/z MS (TOF ES⁺)
8
9 C₂₇H₂₇F₂N₂O₅ [MH]⁺ calcd 497.2; found 497.2; LC-MS t_R : 5.90.

10
11 **1-(4-(3-Aminoprop-1-yn-1-yl)benzyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic**
12 **acid hydrochloride (22).** Ethyl 1-(4-(3-((tert-butoxycarbonyl)amino)prop-1-yn-1-yl)benzyl)-5,8-
13
14 difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (**21**) (230 mg, 0.46 mmol) was dispersed in a
15
16 mixture of 1,4-dioxane/1 M HCl_(aq) (1:1, 2 mL) and heated at 80 °C for 3.5 h, then at rt overnight
17
18 (TLC analysis (MeOH/DCM 1:9) indicated complete *N*-Boc deprotection after 1.5 h). Heating was
19
20 continued under reflux for a further 5 h, before cooling and concentration under reduced pressure,
21
22 to give 205 mg of pale yellow solid (quantitative yield). ¹H NMR (400 MHz, DMSO) δ 14.75 (s,
23
24 1H), 9.14 (s, 1H), 8.45 (s, 3H), 7.77 (ddd, $J = 13.7, 9.1, 4.3$ Hz, 1H), 7.56–7.31 (m, 3H), 7.21 (d, J
25
26 = 8.3 Hz, 2H), 5.90 (d, $J = 4.0$ Hz, 2H), 3.97 (s, 2H); ¹³C NMR (101 MHz, DMSO) δ 177.04,
27
28 165.18, 158.46 (d, $J_{CF} = 261.7$ Hz), 152.63, 147.97 (d, $J_{CF} = 262.4$ Hz), 137.80, 131.87, 130.23,
29
30 126.15, 120.50, 119.70 (d, $J_{CF} = 23.1$ Hz), 119.04, 113.35 (d, $J_{CF} = 13.3$ Hz), 109.46, 85.09, 83.04,
31
32 60.31 (d, $J_{CF} = 4.2$ Hz), 28.93; m/z MS (TOF ES⁺) C₂₀H₁₅F₂N₂O₃ [MH]⁺ calcd 369.1; found 369.1;
33
34 LC-MS t_R : 4.36.

35
36
37
38
39
40 **Ethyl 3-(dimethylamino)-2-(2-fluorobenzoyl)acrylate (24).**⁴⁰ Ethyl-(2-fluorobenzyl)acetate
41
42 (**23**) (1.04 g, 4.95 mmol) was dissolved in DMF (1 mL) and *N,N*-dimethylformamide, dimethyl
43
44 acetal (627 mg, 5.26 mmol, 1 eq) added. The mixture was heated at 100 °C in the microwave
45
46 reactor for 30 min, before pouring onto ice water (200 mL), and stirring for 5 min. The aqueous
47
48 slurry was then extracted with Et₂O (20 mL), before saturating the aqueous layer with NaCl and
49
50 extracting again with Et₂O (2 x 20 mL). The combined organic layers were washed with brine (30
51
52 mL) before concentration to give 1.185 g of yellow oil (90%). ¹H NMR (400 MHz, CDCl₃) δ 7.75
53
54 (s, 1H), 7.59 (s, 1H), 7.45 – 7.31 (m, 1H), 7.16 (ddd, $J = 7.6, 0.9$ Hz, 1H), 7.01 (ddd, $J = 10.3, 8.3,$
55
56
57
58
59
60

0.8 Hz, 1H), 3.95 (q, $J = 7.1$ Hz, 2H), 3.28 (s, 3H), 2.90 (s, 3H), 0.88 (t, $J = 7.1$ Hz, 3H); m/z MS (TOF ES⁺) C₁₄H₁₇FNO₃ [MH]⁺ calcd 266.1; found 266.2.1; LC-MS t_R : 5.66.

Ethyl 1-(4-methoxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (25a).⁴⁰ Ethyl 3-(dimethylamino)-2-(2-fluorobenzoyl)acrylate (**24**) (100 mg, 0.38 mmol) and *p*-anisidine (47 mg, 0.38 mmol, 1 eq) were dissolved in dry DMF (2 mL) and heated at 140 °C in the microwave reactor for 1 h. TLC analysis (EtOAc/PE 1:1) indicated partial progression, so the mixture was heated at 140 °C (oil bath) over the weekend. LC-MS analysis after this time indicated only 1 major peak, the mixture was poured on to ice water, and the resulting precipitate filtered, washed with water, PE and dried, to give 87 mg of pale brown solid (71%). ¹H NMR (400 MHz, CDCl₃) δ 8.55 (dd, $J = 8.0, 1.4$ Hz, 1H), 8.50 (s, 1H), 7.51 (ddd, $J = 8.6, 7.1, 1.6$ Hz, 1H), 7.45–7.37 (m, 1H), 7.37–7.28 (m, 2H), 7.16–7.04 (m, 2H), 6.99 (d, $J = 8.4$ Hz, 1H), 4.40 (q, $J = 7.1$ Hz, 2H), 3.92 (s, 3H), 1.40 (t, $J = 7.1$ Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 174.59, 165.95, 160.61, 149.25, 141.14, 133.52, 132.40, 128.70, 128.62, 127.65, 125.33, 117.85, 115.55, 111.39, 61.08, 55.88, 14.59; m/z MS (TOF ES⁺) C₁₉H₁₈NO₄ [MH]⁺ calcd 324.1; found 324.2; LC-MS t_R : 5.27.

Ethyl 1-([1,1'-biphenyl]-4-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (25b). Ethyl 3-(dimethylamino)-2-(2-fluorobenzoyl)acrylate (**24**) (100 mg, 0.38 mmol) and 4-aminobiphenyl (64 mg, 0.38 mmol, 1 eq) were dissolved in dry DMF (2 mL) and heated at 140 °C (oil bath) over the weekend. LC-MS analysis after this time indicated only 1 major peak, the mixture was poured on to ice water, and the resulting precipitate filtered, washed with water, PE and dried, to give 85 mg of yellow solid (61%). ¹H NMR (400 MHz, CDCl₃) δ 8.64–8.50 (m, 2H), 7.88–7.77 (m, 2H), 7.72–7.64 (m, 2H), 7.64–7.48 (m, 5H), 7.48–7.36 (m, 2H), 7.08 (dd, $J = 13.6, 4.9$ Hz, 1H), 4.41 (q, $J = 7.1$ Hz, 2H), 1.41 (t, $J = 7.1$ Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 174.58, 165.83, 148.84, 143.27, 140.75, 139.83, 139.48, 132.50, 129.27, 129.16, 128.63, 128.46, 127.87, 127.74, 127.39, 125.47, 117.81, 111.63, 61.13, 14.60; m/z MS (TOF ES⁺) C₂₄H₂₀NO₃ [MH]⁺ calcd 370.1; found 370.2; LC-MS t_R : 5.77.

1
2
3 **1-(4-Methoxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (26a).** Ethyl 1-(4-
4 methoxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (**25a**) (68 mg, 0.21 mmol) was
5 hydrolysed according to general procedure D. On acidification of the aqueous layer during workup,
6 a pink precipitate formed. This was collected by filtration (vacuum) and washed with water and PE,
7 before drying to give 46 mg of pink solid (74%). ¹H NMR (400 MHz, CDCl₃) δ 14.92 (s, 1H), 8.80
8 (s, 1H), 8.56 (dd, *J* = 8.1, 1.3 Hz, 1H), 7.68 (ddd, *J* = 8.7, 7.1, 1.6 Hz, 1H), 7.57 (ddd, *J* = 8.1, 7.1,
9 1.0 Hz, 1H), 7.41–7.28 (m, 2H), 7.17 (d, *J* = 8.5 Hz, 1H), 7.15–7.05 (m, 2H), 3.93 (s, 4H); ¹³C
10 NMR (101 MHz, CDCl₃) δ 178.92, 167.11, 161.03, 149.04, 141.64, 133.90, 132.77, 128.36,
11 126.90, 126.49, 126.07, 118.72, 115.71, 109.02, 55.94; *m/z* MS (TOF ES⁺) C₁₇H₁₄NO₄ [MH]⁺ calcd
12 296.1; found 296.2; LC-MS *t*_R: 5.25.

13
14
15
16
17
18
19
20
21
22
23
24
25 **1-([1,1'-Biphenyl]-4-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (26b).** Ethyl 1-([1,1'-
26 biphenyl]-4-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (**25b**) (68 mg, 0.18 mmol) was
27 hydrolysed according to general procedure D. On extracting the reaction mixture with Et₂O, the
28 lithium salt of the product was found to suspend in the organic layer. This was collected by
29 filtration (vacuum), before suspending in 2 M HCl (aq) (10 mL), and extracting the acidic suspension
30 with DCM (2 x 10 mL). Concentration of the DCM layers gave 35 mg of pale yellow solid (57%).
31 ¹H NMR (400 MHz, CDCl₃) δ 14.88 (s, 1H), 8.86 (s, 1H), 8.59 (dt, *J* = 5.1, 2.5 Hz, 1H), 7.93–7.79
32 (m, 2H), 7.76–7.64 (m, 3H), 7.60 (ddd, *J* = 8.1, 7.1, 1.0 Hz, 1H), 7.57–7.39 (m, 5H), 7.27 (d, *J* =
33 8.1 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 178.96, 166.99, 148.68, 143.94, 141.27, 139.21,
34 139.10, 134.01, 129.32, 129.31, 128.65, 127.54, 127.42, 127.01, 126.61, 126.11, 118.68, 109.23;
35 *m/z* MS (TOF ES⁺) C₂₂H₁₆NO₃ [MH]⁺ calcd 342.1; found 342.2; LC-MS *t*_R: 5.72.

36
37
38
39
40
41
42
43
44
45
46
47
48
49 **Ethyl 1-((1-(*tert*-butoxycarbonyl)piperidin-4-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-**
50 **carboxylate (27)** Ethyl 3-(dimethylamino)-2-(2-fluorobenzoyl)acrylate (**24**) (500 mg, 1.88 mmol),
51 *N*-Boc-(4-aminomethyl)piperidine (404 mg, 1.88 mmol, 1 eq) and Cs₂CO₃ (735 mg, 2.26 mmol, 1.2
52 eq) were dissolved in dry DMF (10 mL) under an atmosphere of nitrogen gas. The mixture was
53 heated at 100 °C (oil bath) for 6.5 h, after which time TLC analysis (EtOAc/PE 6:4) indicated
54
55
56
57
58
59
60

1
2
3 disappearance of starting material. The mixture was cooled to rt, before diluting with ice water and
4
5 stirring for 30 min. The resulting precipitate was collected by filtration (vacuum) to give 619 mg of
6
7 off-white solid (79%). ^1H NMR (400 MHz, CDCl_3) δ 8.56 (dd, $J = 8.1, 1.5$ Hz, 1H), 8.40 (s, 1H),
8
9 7.70 (ddd, $J = 8.6, 7.1, 1.6$ Hz, 1H), 7.46 (td, $J = 7.6, 0.8$ Hz, 1H), 7.41 (d, $J = 8.5$ Hz, 1H), 4.41 (q,
10
11 $J = 7.1$ Hz, 2H), 4.34 – 3.84 (m, 4H), 2.63 (t, $J = 12.2$ Hz, 2H), 2.09 (ddt, $J = 15.4, 7.6, 3.8$ Hz, 1H),
12
13 1.60 (d, $J = 17.3$ Hz, 2H), 1.46 (s, 9H), 1.42 (t, $J = 7.1$ Hz, 3H), 1.37–1.10 (m, 2H); ^{13}C NMR (101
14
15 MHz, CDCl_3) δ 174.32, 166.09, 154.70, 149.49, 139.07, 132.76, 129.51, 128.49, 125.34, 115.67,
16
17 110.94, 79.99, 61.17, 59.33, 43.40, 35.69, 29.83, 28.56, 14.60; m/z MS (TOF ES^+) $\text{C}_{23}\text{H}_{31}\text{N}_2\text{O}_5$
18
19 $[\text{MH}]^+$ calcd 415.2; found 415.3; LC-MS t_R : 5.42.

20
21
22
23 **1-((1-(*tert*-Butoxycarbonyl)piperidin-4-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic**
24
25 **acid (28).** Ethyl 1-((1-(*tert*-butoxycarbonyl)piperidin-4-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-
26
27 carboxylate (**27**) (250 mg, 0.60 mmol) was dispersed in THF/water (1:1, 6 mL) and the flask
28
29 atmosphere purged with nitrogen gas. $\text{LiOH}\cdot\text{H}_2\text{O}$ (101 mg, 2.41 mmol, 4 eq) was added, and the
30
31 mixture stirred at rt overnight. TLC analysis (MeOH/DCM 5:95) indicated conversion was
32
33 complete. The mixture was diluted with water (20 mL) and washed with Et_2O (30 mL), before
34
35 careful acidification ($\sim\text{pH}$ 4-5) by dropwise addition of 2 M HCl (aq), causing a precipitate to form.
36
37 This was collected by filtration (vacuum) to give 202 mg of off-white solid (87%). ^1H NMR (400
38
39 MHz, CDCl_3) δ 14.85 (s, 1H), 8.69 (s, 1H), 8.58 (dd, $J = 8.1, 1.5$ Hz, 1H), 7.87 (ddd, $J = 8.7, 7.2,$
40
41 1.6 Hz, 1H), 7.68–7.54 (m, 2H), 4.19 (s, 4H), 2.63 (t, $J = 12.0$ Hz, 2H), 2.11 (dtd, $J = 15.4, 7.7, 3.9$
42
43 Hz, 1H), 1.83–1.52 (m, $J = 13.5$ Hz, 2H), 1.45 (d, $J = 7.0$ Hz, 9H), 1.32 (dt, $J = 23.1, 13.5$ Hz, 2H);
44
45 ^{13}C NMR (101 MHz, CDCl_3) δ 178.62, 167.03, 154.66, 148.79, 139.62, 134.26, 127.79, 126.85,
46
47 126.48, 116.46, 108.82, 80.13, 59.94, 43.06, 36.02, 29.82, 28.54; m/z MS (TOF ES^+) $\text{C}_{21}\text{H}_{27}\text{N}_2\text{O}_5$
48
49 $[\text{MH}]^+$ calcd 387.2; found 387.2; LC-MS t_R : 5.45.

50
51
52
53
54 **4-Oxo-1-(piperidin-4-ylmethyl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride (29).**
55
56 1-((1-(*tert*-Butoxycarbonyl)piperidin-4-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
57
58 (**28**) (155 mg, 0.40 mmol) was dissolved in DCM (2 mL) with stirring at rt, before addition of 4M
59
60

HCl in 1,4-dioxane (2 mL). The mixture was stirred at rt for 1 h, before addition of PE, followed by collection of the resulting precipitate by filtration (vacuum). The collected solid was further washed with PE, before drying to give 149 mg of off-white solid (quantitative yield). ^1H NMR (400 MHz, DMSO) δ 9.18–8.95 (m, J = 16.9 Hz, 2H), 8.89–8.62 (m, J = 10.1 Hz, 1H), 8.41 (dd, J = 8.1, 1.5 Hz, 1H), 8.11 (d, J = 8.7 Hz, 1H), 7.99 (ddd, J = 8.7, 7.1, 1.6 Hz, 1H), 7.69 (dd, J = 11.2, 3.9 Hz, 1H), 4.56 (d, J = 7.4 Hz, 2H), 3.23 (d, J = 12.5 Hz, 2H), 2.75 (q, J = 12.3 Hz, 2H), 2.16 (ddd, J = 11.2, 7.5, 3.6 Hz, 1H), 1.71 (d, J = 12.8 Hz, 2H), 1.60–1.38 (m, 2H); ^{13}C NMR (101 MHz, DMSO) δ 177.83, 166.08, 149.81, 139.52, 134.30, 126.43, 125.97, 125.61, 118.45, 107.40, 57.13, 42.36, 32.69, 25.50; m/z MS (TOF ES⁺) $\text{C}_{16}\text{H}_{19}\text{N}_2\text{O}_3$ $[\text{MH}]^+$ calcd 287.1; found 287.2; LC-MS t_{R} : 3.70.

Ethyl 4-oxo-1-(piperidin-4-ylmethyl)-1,4-dihydroquinoline-3-carboxylate hydrochloride (30). Ethyl 1-((1-(*tert*-butoxycarbonyl)piperidin-4-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (**27**) (342 mg, 0.83 mmol) was dissolved in DCM (2 mL) and stirred at rt before addition of 4M HCl in 1,4-dioxane (2 mL). The mixture was stirred at rt for 1 h before addition of PE and attempted collection of the resulting precipitate by filtration (vacuum). However, the product was found to be hygroscopic, so the solid was redissolved in MeOH/DCM and combined with the filtrate, before concentration under reduced pressure, to give 325 mg of off-white solid (quantitative yield). ^1H NMR (400 MHz, DMSO) δ 9.11 (d, J = 10.1 Hz, 1H), 8.90 (d, J = 9.9 Hz, 1H), 8.68 (s, 1H), 8.26 (dd, J = 8.0, 1.5 Hz, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.83–7.74 (m, 1H), 7.49 (t, J = 7.5 Hz, 1H), 4.35 (d, J = 7.3 Hz, 2H), 4.23 (q, J = 7.1 Hz, 2H), 3.23 (d, J = 12.3 Hz, 2H), 2.86–2.64 (m, 2H), 2.13 (dd, J = 9.1, 5.8 Hz, 1H), 1.70 (d, J = 12.8 Hz, 2H), 1.50 (td, J = 15.6, 3.6 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H); ^{13}C NMR (101 MHz, DMSO) δ 172.79, 164.78, 149.74, 139.00, 132.72, 128.35, 126.46, 124.96, 117.54, 109.70, 59.82, 56.47, 42.38, 32.53, 25.58, 14.36; m/z MS (TOF ES⁺) $\text{C}_{18}\text{H}_{23}\text{N}_2\text{O}_3$ $[\text{MH}]^+$ calcd 315.2; found 315.2; LC-MS t_{R} : 3.67.

1-((1-Benzylpiperidin-4-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (31). Ethyl 4-oxo-1-(piperidin-4-ylmethyl)-1,4-dihydroquinoline-3-carboxylate hydrochloride (**30**) (80 mg, 0.23 mmol), K_2CO_3 (79 mg, 0.57 mmol, 2.5 eq), BnBr (47 mg, 0.28 mmol, 1.2 eq) were dispersed

1
2
3 in MeCN (2 mL) and stirred at rt overnight. MeCN was removed under reduced pressure, and the
4
5 residue dispersed in water, causing a precipitate to form. This was collected by filtration (vacuum),
6
7 and washed with PE to give 60 mg of off-white solid. This was purified by FCC (MeOH/DCM
8
9 0:100 to 10:90) to give 48 mg of glassy solid. This was taken up in water/THF (1:1, 4 mL), and the
10
11 vessel purged with nitrogen gas, before addition of LiOH.H₂O (39 mg, 0.92 mmol, 4 eq). The
12
13 mixture was stirred at rt overnight, before diluting with water (20 mL) and washing with Et₂O (20
14
15 mL). The aqueous layer was then neutralised with careful addition of 2M HCl_(aq), before extraction
16
17 with EtOAc (3 x 20 mL). Finally, concentration of the EtOAc layers gave 35 mg of off-white solid
18
19 (40%). ¹H NMR (400 MHz, DMSO) δ 15.23 (s, 1H), 9.01 (s, 1H), 8.40 (dd, *J* = 8.1, 1.5 Hz, 1H),
20
21 8.10 (d, *J* = 8.7 Hz, 1H), 7.97 (ddd, *J* = 8.7, 7.0, 1.6 Hz, 1H), 7.67 (t, *J* = 7.2 Hz, 1H), 7.39–7.15 (m,
22
23 5H), 4.50 (d, *J* = 7.4 Hz, 2H), 3.41 (s, 2H), 2.78 (d, *J* = 11.4 Hz, 2H), 1.95–1.62 (m, 3H), 1.56 –
24
25 1.27 (m, 4H); ¹³C NMR (101 MHz, DMSO) δ 177.73, 166.07, 149.64, 139.54, 137.41, 134.27,
26
27 128.62, 128.10, 126.79, 126.36, 125.91, 125.51, 118.45, 107.26, 62.13, 58.12, 52.44, 34.95, 28.70;
28
29 *m/z* MS (TOF ES⁺) C₂₃H₂₅N₂O₃ [MH]⁺ calcd 377.2; found 377.2; LC-MS *t*_R: 4.16.

30
31
32
33
34 **4-Oxo-1-((1-(phenylcarbamoyl)piperidin-4-yl)methyl)-1,4-dihydroquinoline-3-carboxylic**
35
36 **acid (32)**. Ethyl 4-oxo-1-(piperidin-4-ylmethyl)-1,4-dihydroquinoline-3-carboxylate hydrochloride
37
38 **(30)** (80 mg, 0.23 mmol) was dispersed in DCM (2 mL), with addition of DIPEA (0.060 mL, 0.35
39
40 mmol, 1.5 eq) and stirred at rt, before addition of phenyl isocyanate (0.027 mL, 0.25 mmol, 1.1 eq).
41
42 The mixture was stirred at rt overnight. Further phenyl isocyanate (0.2 eq) with stirring at rt for a
43
44 further 3 h, before diluting the reaction mixture with EtOAc (30 mL) and washing with 2 M NaOH
45
46 _(aq) (20 mL), 2M HCl_(aq) (20 mL) and brine (20 mL). The organic layer was concentrated and
47
48 further purified by FCC (eluent MeOH/DCM 0:100 to 10:90) to give 88 mg of yellow solid. This
49
50 was taken up in water/THF (1:1, 4 mL), and the vessel purged with nitrogen gas, before addition of
51
52 LiOH.H₂O (39 mg, 0.92 mmol, 4 eq). The mixture was stirred at rt overnight, before diluting with
53
54 water (20 mL) and washing with Et₂O (20 mL). The aqueous layer was then acidified (~pH 4) with
55
56 2M HCl_(aq), causing a precipitate to form. This was collected by filtration (vacuum) to give 20 mg
57
58
59
60

1
2
3 of off-white solid (22%). ^1H NMR (400 MHz, DMSO) δ 15.24 (s, 1H), 9.05 (s, 1H), 8.46 (s, 1H),
4
5 8.42 (dd, $J = 8.1, 1.4$ Hz, 1H), 8.14 (d, $J = 8.7$ Hz, 1H), 7.99 (ddd, $J = 8.6, 7.1, 1.4$ Hz, 1H), 7.69
6
7 (dd, $J = 7.5$ Hz, 1H), 7.44 (d, $J = 7.6$ Hz, 2H), 7.21 (dd, $J = 7.9$ Hz, 2H), 6.91 (dd, $J = 7.3$ Hz, 1H),
8
9 4.53 (d, $J = 7.5$ Hz, 2H), 4.13 (d, $J = 13.4$ Hz, 2H), 2.68 (t, $J = 12.1$ Hz, 2H), 2.24–1.97 (m, 1H),
10
11 1.54 (d, $J = 10.9$ Hz, 2H), 1.28 (ddd, $J = 19.5, 9.8, 6.2$ Hz, 2H); ^{13}C NMR (101 MHz, DMSO) δ
12
13 177.78, 166.09, 154.73, 149.68, 140.68, 139.58, 134.28, 128.23, 126.38, 125.94, 125.56, 121.54,
14
15 119.50, 118.47, 107.32, 57.81, 43.47, 35.12, 28.63; m/z MS (TOF ES⁺) $\text{C}_{23}\text{H}_{24}\text{N}_3\text{O}_4$ $[\text{MH}]^+$ calcd
16
17 406.2; found 406.2; LC-MS t_{R} : 5.13.
18
19
20
21
22

23 Pharmacology.

24
25 *Radioligand binding assays.* FlpInCHO cells stably expressing the human M₁ muscarinic
26
27 acetylcholine receptor (FlpInCHO-hM₁ mAChR) were generated as described previously⁴¹ and
28
29 maintained in DMEM containing 5% FBS under humidified conditions at 37°C and 5% CO₂.
30
31 Radioligand binding experiments were performed on whole cells, seeded at 20,000 cells per well in
32
33 complete DMEM into 96-well ISOPATE TC plates. Next, cells were allowed to grow for 8 hours
34
35 at 37 °C, then serum starved overnight. Following a wash with phosphate-buffered saline (100 μl)
36
37 the cells were then resuspended in binding buffer (10 mM HEPES, 100 mM NaCl, 10 mM MgCl₂,
38
39 pH 7.4). Assays were performed in a total volume of 200 μl with a 1/10 dilution of drug, for a
40
41 duration of 4 hours at 4 °C. Assays were terminated by buffer removal followed by rapid washing,
42
43 twice, with ice-cold 0.9% NaCl (100 μl). Plates were allowed to dry inverted for 30 min; OptiPhase
44
45 Supermix scintillation cocktail (100 μl) was added, plates were sealed (TopSealTM), and
46
47 radioactivity was measured in a MicroBeta² LumiJET microplate counter. All inhibition binding
48
49 experiments were performed with 0.1 nM [³H]-NMS (K_{D} concentration) in presence of increasing
50
51 concentrations of ACh with or without increasing concentrations of BQCA analogues.
52
53
54
55

56
57 *Intracellular calcium mobilisation assays.* On the day prior to the experiment, FlpInCHO-hM₁
58
59 mAChR cells were seeded at 20,000 cells per well (100 μL final volume per well) into clear 96-well
60

plates in DMEM containing 5% FBS and incubated 8 hours under humidified conditions at 37°C and 5% CO₂ prior serum starving the cells overnight. On the day of the experiment, the assay plates were washed once with 100 μL per well of phosphate buffered saline. The cells were then incubated with Ca²⁺ assay buffer (150 mM NaCl, 2.6 mM KCl, 1.18 mM MgCl₂·6H₂O, 10 mM D-glucose, 10 mM HEPES, 2.2 mM CaCl₂·2H₂O, 0.5% (w/v) bovine serum albumin (BSA), and 4 mM Probenecid, pH = 7.4) containing 1 μM Fluo-4-AM for 1 hour under humidified conditions at 37°C and 0% CO₂. Each assay plate was then loaded into a FLEXstation™ (Molecular Devices Inc., Sunnyvale, CA) with its stock compound plate. The FLEXstation measured fluorescence over a 100 second time period using 485 nm excitation and 520 nm emission wavelengths and performed the addition of drugs (1/10 dilution) at the 20 second time point. For all interaction studies, ACh and BQCA (or its analogue) were co-added (simultaneously) at 20 seconds. For each, the peak of maximum fluorescence between the time 20 to 100 seconds was chosen and corrected to the baseline (fluorescence from time 0 to 19 seconds), then normalised to 100 μM ATP as internal control.

Data analysis. Competition binding curves between [³H]NMS and ACh in the absence or presence of BQCA or its analogues, were fitted to the allosteric ternary complex model as described previously⁷. Competition-binding curves between [³H]NMS and ACh in the absence or presence of BQCA or analogues were fitted to the following allosteric ternary complex model (equation 1):

$$Y = \frac{[A]}{[A] + \left(\frac{K_A K_B}{\alpha' [B] + K_B} \right) \left(1 + \frac{[I]}{K_I} + \frac{[B]}{K_B} + \frac{\alpha [I][B]}{K_I K_B} \right)} \quad (1)$$

where Y is percentage (vehicle control) binding, [A], [B], and [I] are the concentrations of [³H]NMS, BQCA (or analogues) and ACh respectively, K_A and K_B are the equilibrium dissociation constants of [³H]NMS and BQCA, respectively, K_B is the equilibrium dissociation constant of CCh and α' and α are the cooperativities (or analogues) between BQCA and [³H]NMS or CCh respectively. Values of α (or α') > 1 denote positive cooperativity; values < 1 (but > 0) denote negative cooperativity, and values =1 denote neutral cooperativity.

Functional data were analysed using an operational model of allosterism and agonism according to equation 2:^{10,42}

$$E = \frac{E_m (\tau_A [A] (K_B + \alpha \beta [B]) + \tau_B [B] K_A)^n}{([A] K_B + K_A K_B + [B] K_A + \alpha [A] [B])^n + (\tau_A [A] (K_B + \alpha \beta [B]) + \tau_B [B] K_A)^n} \quad (2)$$

where E_m is the maximum possible cellular response, $[A]$ and $[B]$ are the concentrations of orthosteric and allosteric ligands, respectively, K_A and K_B are the equilibrium dissociation constant of the orthosteric and allosteric ligands, respectively, τ_A and τ_B are operational measures of orthosteric and allosteric ligand efficacy (which incorporate both signal efficiency and receptor density), respectively, α is the binding cooperativity parameter between the orthosteric and allosteric ligand, and β denotes the magnitude of the allosteric effect of the modulator on the efficacy of the orthosteric agonist. In all instances, the equilibrium dissociation constant of each agonist and BQCA (or analogues) was fixed to that determined from the binding assays.

AUTHOR INFORMATION

Corresponding Author

*For P.J.S.: phone: +61 (0)3 9903 9542; E-mail: Peter.Scammells@monash.edu. For A.C.: phone: +61 (0)3 9903 9067; E-mail: Arthur.Christopoulos@monash.edu.

Notes

§ These authors contributed equally to this work.

The authors declare no competing financial interest.

ACKNOWLEDGMENT

This research was supported by Discovery grant DP110100687 of the Australian Research Council and Program Grant 519461 of the National Health and Medical Research Council (NHMRC) of Australia. A.C. and P.M.S. are Principal Research Fellows of the NHMRC.

ABBREVIATIONS USED

BQCA, benzyl quinolone carboxylic acid (1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid); CHO, Chinese hamster ovary; DIPEA, *N,N*-diisopropylethylamine; FCC, flash-column chromatography; PE, petroleum-ether 40-60; PLC, preparative layer chromatography; TEA, triethylamine.

REFERENCES

- (1) Medeiros, R. R.; Kitazawa, M. M.; Caccamo, A. A.; Baglietto-Vargas, D. D.; Estrada-Hernandez, T. T.; Cribbs, D. H. D.; Fisher, A. A.; LaFerla, F. M. F. Loss of Muscarinic M₁ Receptor Exacerbates Alzheimer's Disease-Like Pathology and Cognitive Decline. *Am. J. Pathol.* **2011**, *179*, 980–991.
- (2) Langmead, C. J.; Watson, J.; Reavill, C. Muscarinic acetylcholine receptors as CNS drug targets. *Pharmacol. Therapeut.* **2008**, *117*, 232–243.
- (3) Holden, M.; Kelly, C. Use of cholinesterase inhibitors in dementia. *Adv. Psychiat. Treat.* **2002**, *8*, 89–96.
- (4) Wess, J.; Eglen, R. M.; Gautam, D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. *Nat. Rev. Drug Discov.* **2007**, *6*, 721–733.
- (5) Decker, M.; Holzgrabe, U. M₁ Muscarinic Acetylcholine Receptor Allosteric Modulators as Potential Therapeutic Opportunities for Treating Alzheimer's Disease. *Med. Chem. Commun.* **2012**, *3*, 752.

1
2
3 (6) Ma, L.; Seager, M. A.; Seager, M. A.; Wittmann, M.; Jacobson, M.; Bickel, D.; Burno, M.;
4 Jones, K.; Graufelds, V. K.; Xu, G.; Pearson, M.; McCampbell, A.; Gaspar, R.; Shughrue, P.;
5 Danziger, A.; Regan, C.; Flick, R.; Pascarella, D.; Garson, S.; Doran, S.; Kreatsoulas, C.; Veng, L.;
6 Lindsley, C. W.; Shipe, W. D.; Kuduk, S. D.; Sur, C.; Kinney, G.; Seabrook, G. R.; Ray, W. J.
7 Selective activation of the M₁ muscarinic acetylcholine receptor achieved by allosteric potentiation.
8 *P. Natl. Acad. Sci. USA* **2009**, *106*, 15950–15955.

9
10
11
12
13
14
15
16 (7) Canals, M.; Lane, J. R.; Wen, A.; Scammells, P. J.; Sexton, P. M.; Christopoulos, A. A
17 Monod-Wyman-Changeux Mechanism Can Explain G Protein-coupled Receptor (GPCR) Allosteric
18 Modulation. *J. Biol. Chem.* **2012**, *287*, 650–659.

19
20
21
22
23 (8) Shirey, J. K.; Brady, A. E.; Jones, P. J.; Davis, A. A.; Bridges, T. M.; Kennedy, J. P.;
24 Jadhav, S. B.; Menon, U. N.; Xiang, Z.; Watson, M. L.; Christian, E. P.; Doherty, J. J.; Quirk, M.
25 C.; Snyder, D. H.; Lah, J. J.; Levey, A. I.; Nicolle, M. M.; Lindsley, C. W.; Conn, P. J. A Selective
26 Allosteric Potentiator of the M₁ Muscarinic Acetylcholine Receptor Increases Activity of Medial
27 Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning. *J. Neurosci.* **2009**, *29*,
28 14271–14286.

29
30
31
32
33
34
35
36 (9) Yang, F. V.; Shipe, W. D.; Bunda, J. L.; Nolt, M. B.; Wisnoski, D. D.; Zhao, Z.; Barrow, J.
37 C.; Ray, W. J.; Ma, L.; Wittmann, M.; Seager, M. A.; Koeplinger, K. A.; Hartman, G. D.; Lindsley,
38 C. W. Parallel synthesis of N-biaryl quinolone carboxylic acids as selective M₁ positive allosteric
39 modulators. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 531–536.

40
41
42
43
44
45 (10) Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric GPCR modulators: taking advantage
46 of permissive receptor pharmacology. *Trends Pharmacol. Sci.* **2007**, *28*, 382–389.

47
48
49 (11) Conn, P. J.; Kuduk, S. D.; Doller, D. Drug Design Strategies for GPCR Allosteric
50 Modulators. *Annu. Rep. Med. Chem.* **2012**, *47*, 441–457.

51
52
53
54 (12) Gould, R. G.; Jacobs, W. A. The synthesis of certain substituted quinolines and 5, 6-
55 benzoquinolines. *J. Am. Chem. Soc.* **1939**, *61*, 2890–2895.

1
2
3 (13) Cao, X.; You, Q. D.; Li, Z.-Y.; Yang, Y.; Wang, X. J. Microwave-Assisted Simple
4 Synthesis of Substituted 4-Quinolone Derivatives. *Synth. Commun.* **2009**, *39*, 4375–4383.

5
6
7 (14) Eaton, P. E.; Carlson, G. R.; Lee, J. T. Phosphorus pentoxide-methanesulfonic acid.
8 Convenient alternative to polyphosphoric acid. *J. Org. Chem.* **2001**, *38*, 4071–4073.

9
10
11 (15) Zewge, D.; Chen, C.-Y.; Deer, C.; Dormer, P. G.; Hughes, D. L. A Mild and Efficient
12 Synthesis of 4-Quinolones and Quinolone Heterocycles. *J. Org. Chem.* **2007**, *72*, 4276–4279.

13
14
15 (16) Birch, M.; Sibley, G. E. M.; Law, D.; Oliver, J. D. Antifungal Combination Therapy. *WIPO*
16
17 **2009**, WO 2009/144473.

18
19
20 (17) Maffioli, S. I.; Marzorati, E.; Marazzi, A. Mild and Reversible Dehydration of Primary
21 Amides with PdCl₂ in Aqueous Acetonitrile. *Org. Lett.* **2005**, *7*, 5237–5239.

22
23
24 (18) Koguro, K.; Oga, T.; Mitsui, S.; Orita, R. Novel Synthesis of 5-Substituted Tetrazoles from
25 Nitriles. *Synthesis* **1998**, *29*, 910–914.

26
27
28 (19) Škugor, M. M.; Štimac, V.; Palej, I.; Lugarić, Đ.; Paljetak, H. Č.; Filić, D.; Modrić, M.;
29 Đilović, I.; Gembarovski, D.; Mutak, S.; Haber, V. E.; Holmes, D. J.; Ivezić-Schoenfeld, Z.;
30 Alihodžić, S. Synthesis and Biological Activity of 4"-O-Acyl Derivatives of 14- and 15-Membered
31 Macrolides Linked to ω -Quinolone-Carboxylic Unit. *Bioorg. Med. Chem.* **2010**, *18*, 6547–6558.

32
33
34 (20) Johnson, M. R. Soluble Amide & Ester Pyrazinoylguanidine Sodium Channel Blockers, *US*
35
36
37 *Patent Office* **2009**, US 2009/0324724.

38
39
40 (21) Guicherit, O. M.; Boyd, E. A.; Brunton, S. A.; Price, S.; Stibbard, J. H. A.; Mackinnon, C.
41
42
43 H. Mediators of Hedgehog Signaling Pathways, Compositions and Uses Related Thereto *WIPO*
44
45
46
47 **2006**, WO 2006/050506.

48
49
50 (22) Kuduk, S. D.; Chang, R. K.; Di Marco, C. N.; Ray, W. J.; Ma, L.; Wittmann, M.; Seager, M.
51
52
53 A.; Koeplinger, K. A.; Thompson, C. D.; Hartman, G. D.; Bilodeau, M. T. Quinolizidinone
54
55
56
57
58
59
60 carboxylic acid selective M₁ allosteric modulators: SAR in the piperidine series. *Bioorg. Med.*
Chem. Lett. **2011**, *21*, 1710–1715.

1
2
3 (23) Kuduk, S. D.; Chang, R. K.; Di Marco, C. N.; Ray, W. J.; Ma, L.; Wittmann, M.; Seager, M.
4
5 A.; Koeplinger, K. A.; Thompson, C. D.; Hartman, G. D.; Bilodeau, M. T. Quinolizidinone
6
7 Carboxylic Acids as CNS Penetrant, Selective M₁ Allosteric Muscarinic Receptor Modulators. *ACS*
8
9 *Med. Chem. Lett.* **2010**, *1*, 263–267.

10
11 (24) Kuduk, S. D.; Chang, R. K.; Di Marco, C. N.; Pitts, D. R.; Greshock, T. J.; Ma, L.;
12
13 Wittmann, M.; Seager, M. A.; Koeplinger, K. A.; Thompson, C. D.; Hartman, G. D.; Bilodeau, M.
14
15 T.; Ray, W. J. Discovery of a Selective Allosteric M₁ Receptor Modulator with Suitable
16
17 Development Properties Based on a Quinolizidinone Carboxylic Acid Scaffold. *J. Med. Chem.*
18
19 **2011**, *54*, 4773–4780.

20
21 (25) Wise, W. M.; Brandt, W. W. An Investigation of Some Hydroxamic Acids. *J. Am. Chem.*
22
23 *Soc.* **1955**, *77*, 1058–1059.

24
25 (26) Meanwell, N. A. Synopsis of Some Recent Tactical Application of Bioisosteres in Drug
26
27 Design. *J. Med. Chem.* **2011**, *54*, 2529–2591.

28
29 (27) Bell, R. P.; Higginson, W.; Bell, R. P.; Higginson, W. The catalyzed dehydration of
30
31 acetaldehyde hydrate, and the effect of structure on the velocity of protolytic reactions. *P. Roy. Soc.*
32
33 *A-Math. Phy.* **1949**, *197*, 141–159.

34
35 (28) Barbosa, J.; Barrón, D.; Jiménez-Lozano, E.; Sanz-Nebot, V. Comparison Between
36
37 Capillary Electrophoresis, Liquid Chromatography, Potentiometric and Spectrophotometric
38
39 Techniques for Evaluation of pK_a Values of Zwitterionic Drugs in Acetonitrile–Water Mixtures.
40
41 *Anal. Chim. Acta* **2001**, *437*, 309–321.

42
43 (29) Reid, P. R.; Bridges, T. M.; Sheffler, D. J.; Cho, H. P.; Lewis, L. M.; Days, E.; Daniels, J.
44
45 S.; Jones, C. K.; Niswender, C. M.; Weaver, C. D.; Conn, P. J.; Lindsley, C. W.; Wood, M. R.
46
47 Discovery and optimization of a novel, selective and brain penetrant M₁ positive allosteric
48
49 modulator (PAM): The development of ML169, an MLPCN probe. *Bioorg. Med. Chem. Lett.* **2011**,
50
51 *21*, 2697–2701.

1
2
3 (30) Kuduk, S. D.; Di Marco, C. N.; Cofre, V.; Pitts, D. R.; Ray, W. J.; Ma, L.; Wittmann, M.;
4
5 Seager, M. A.; Koeplinger, K. A.; Thompson, C. D.; Hartman, G. D.; Bilodeau, M. T. Pyridine
6
7 containing M₁ positive allosteric modulators with reduced plasma protein binding. *Bioorg. Med.*
8
9 *Chem. Lett.* **2010**, *20*, 657–661.

10
11 (31) Kuduk, S. D.; DiPardo, R. M.; Beshore, D. C.; Ray, W. J.; Ma, L.; Wittmann, M.; Seager,
12
13 M. A.; Koeplinger, K. A.; Thompson, C. D.; Hartman, G. D.; Bilodeau, M. T. Hydroxy cycloalkyl
14
15 fused pyridone carboxylic acid M₁ positive allosteric modulators. *Bioorg. Med. Chem. Lett.* **2010**,
16
17 *20*, 2538–2541.

18
19 (32) Kuduk, S. D.; Di Marco, C. N.; Cofre, V.; Pitts, D. R.; Ray, W. J.; Ma, L.; Wittmann, M.;
20
21 Veng, L.; Seager, M. A.; Koeplinger, K. A.; Thompson, C. D.; Hartman, G. D.; Bilodeau, M. T. N-
22
23 Heterocyclic derived M₁ positive allosteric modulators. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 1334–
24
25 1337.

26
27 (33) Kuduk, S. D.; Di Marco, C. N.; Cofre, V.; Ray, W. J.; Ma, L.; Wittmann, M.; Seager, M. A.;
28
29 Koeplinger, K. A.; Thompson, C. D.; Hartman, G. D.; Bilodeau, M. T. Fused heterocyclic M₁
30
31 positive allosteric modulators. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 2769–2772.

32
33 (34) Kuduk, S. D.; Chang, R. K.; Greshock, T. J.; Ray, W. J.; Ma, L.; Wittmann, M.; Seager, M.
34
35 A.; Koeplinger, K. A.; Thompson, C. D.; Hartman, G. D.; Bilodeau, M. T. Identification of Amides
36
37 as Carboxylic Acid Surrogates for Quinolizidinone-Based M₁ Positive Allosteric Modulators. *ACS*
38
39 *Med. Chem. Lett.* **2012**, *3*, 1070–1074.

40
41 (35) Podányi, B.; Keresztúri, G.; Vasvári-Debreczy, L.; Hermeecz, I.; Tóth, G. An NMR Study of
42
43 Halogenated 1,4-Dihydro-1-ethyl-4-oxoquinoline-3-carboxylates. *Magn. Reson. Chem.* **1996**, *34*,
44
45 972–978.

46
47 (36) Lauer, W. M.; Arnold, R. T.; Tiffany, B.; Tinker, J. The Synthesis of Some
48
49 Chloromethoxyquinolines. *J. Am. Chem. Soc.* **2001**, *68*, 1268–1269.

1
2
3 (37) Zhang, Y.; Guiguemde, W. A.; Sigal, M.; Zhu, F.; Connelly, M. C.; Nwaka, S.; Guy, R. K.
4
5 Synthesis and structure–activity relationships of antimalarial 4-oxo-3-carboxyl quinolones. *Bioorg.*
6
7 *Med. Chem.* **2010**, *18*, 2756–2766.


8
9 (38) Lindsley, C. W.; Shipe, W. D.; Yang, F. V.; Bunda, J. L. Benzyl-Substituted Quinolone M₁
10
11 Receptor Positive Allosteric Modulators. *WIPO* **2008**, WO 2008/002621.

12
13 (39) Casara, P.; Jund, K.; Bey, P. General synthetic access to α -allenyl amines and α -allenyl- α -
14
15 aminoacids as potential enzyme activated irreversible inhibitors of PLP dependent enzymes.
16
17 *Tetrahedron Lett.* **2001**, *25*, 1891–1894.

18
19 (40) Bunce, R. A.; Lee, E. J.; Grant, M. T. Ethyl 1,4-dihydro-4-oxo-3-quinolinecarboxylates by a
20
21 tandem addition-elimination-SNAr reaction. *J. Heterocyclic Chem.* **2011**, *48*, 620–625.


22
23 (41) Avlani, V. A.; Gregory, K. J.; Morton, C. J.; Parker, M. W.; Sexton, P. M.; Christopoulos,
24
25 A. Critical Role for the Second Extracellular Loop in the Binding of Both Orthosteric and Allosteric
26
27 G Protein-coupled Receptor Ligands. *J. Biol. Chem.* **2007**, *282*, 25677–25686.

28
29 (42) Aurelio, L.; Valant, C.; Flynn, B. L.; Sexton, P. M.; Christopoulos, A.; Scammells, P. J.
30
31 Allosteric Modulators of the Adenosine A₁ Receptor: Synthesis and Pharmacological Evaluation of
32
33 4-Substituted 2-Amino-3-benzoylthiophenes. *J. Med. Chem.* **2009**, *52*, 4543–4547.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Scheme 1: Synthesis of BQCA analogues with varied 5- and 8- substituents^a


^aReagents and conditions: (a) diethylethoxymethylene malonate, 100-120 °C, 71-86%; (b) diethylethoxymethylene malonate, Et₃N, 100 °C, 79%; (c) Eaton's reagent, 90-100 °C, 35-84%; (d) H₂, 10% Pd/C, EtOH, 100%; (e) alkyl halide, KI, K₂CO₃, DMF, rt, 32-86%; (f) 1,4-dioxane/HCl_(aq), reflux, 62-90%; (g) LiOH.H₂O, THF, water, rt, 49-98%; (h) i. 1 M NaOH_(aq), 1,4-dioxane, 80 °C; ii. LiOH.H₂O, reflux; iii. microwave 160 °C, 1 hour; 53%.

Scheme 2: Synthesis of amide/*N*-acyl-sulfonamide derivatives of 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid^a




^aReagents and conditions: (a) i. DCM, 0 °C; ii. Oxalyl chloride, DMF; (b) amine or amine hydrochloride + TEA, DCM, 18-83%; (c) i. HCTU, amine, DMF; ii. DIPEA, DCM, 62-100%; (d) i. methanesulfonamide, DCM, 0 °C; ii. TEA, 0 °C to rt; 39%.

Scheme 3 Synthesis of amide and acid isostere analogues of 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid^a




^aReagents and conditions: (a) 40% MeNH₂ (aq), EtOH, rt, 83%; (b) Ethanolamine, EtOH, rt, 88%; (c) 28-30% NH₃ (aq), EtOH, rt, 88%; (d) i. PdCl₂, MeCN, water, MeOH, THF, rt; ii. 50 °C, 35%; (e) NaN₃, TEA.HCl, toluene, reflux, 38%; (f) Ac₂O, pyridine, 100 °C, 64%.

Scheme 4 Synthesis of 5,8-difluoro-1-(substituted-benzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid analogues^a



^aReagents and conditions: (a) alkyl halide, KI, K₂CO₃, DMF, rt, 67-75%; (b) 2 M HCl (aq), 1,4-dioxane, 80 °C to reflux, 91-96%; (c) Boc₂O, water, rt, 96%; (d) 4-iodobenzyl alcohol, TEA, CuI, PdCl₂(PPh₃)₂, THF, 42%; (e) PPh₃, CBr₄, DCM, 0 °C to rt, 55%; (f) 1 M HCl (aq), 1,4-dioxane, 80 °C to reflux, 100%.

Scheme 5 Synthesis of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing *N*-aryl or *N*-(substituted piperidine-4-methyl) groups^a



^aReagents and conditions: (a) *N,N*-dimethylformamide, dimethyl acetal, DMF, microwave 100 °C, 30 min, 90%; (b) substituted aniline, dry DMF, 140 °C, 61-71%; (c) LiOH.H₂O, THF, water, rt, 57-74%; (d) *N*-Boc-(4-aminomethyl)piperidine, dry DMF, 100 °C, 79%; (e) LiOH.H₂O, THF, water, rt, 22-87%; (f) 4 M HCl/1,4-dioxane, DCM, 100%; (g) BnBr, K₂CO₃, MeCN, rt; (h) phenyl isocyanate, DIPEA, DCM, rt.






Figure 1. Pharmacological characterization of BQCA and 5a in radioligand binding and calcium mobilization assays. (A and B) Radioligand binding experiments using M_1 -expressing CHO cells in presence of a K_D concentration of the radiolabelled antagonist $[^3\text{H}]\text{-NMS}$ (0.1 nM), increasing concentrations of ACh with or without increasing concentrations of either BQCA (A) or 5a (B). (C, D and E) Calcium mobilization experiments. (C) Increasing concentration of ACh, BQCA and 5a alone. (D and E) Increasing concentrations of ACh with or without increasing concentrations of either BQCA (D) or 5a (E). Values represent the mean \pm S.E.M. from at least three to four experiments performed in duplicate.

Table 1: Binding and functional parameters for analogues of BQCA with varying 5- and 8- substituents, bearing an *N*-(4-methoxybenzyl) or *N*-(4-phenylbenzyl) pendant^a




	R ¹	R ²	R ³	R ⁴	p <i>K</i> _B	Log <i>α</i> (<i>α</i>)	Log <i>τ</i> _B (<i>τ</i> _B)	Log <i>αβ</i> (<i>αβ</i>)
BQCA	H	H	OMe	H	4.72 ± 0.07	2.60 ± 0.11 (400)	1.45 ± 0.09 (28)	2.72 ± 0.13 (525)
3a	F	F	OMe	Et	5.12 ± 0.15	0.18 ± 0.09 (1.5)		
3b	F	OMe	OMe	Et	4.82 ± 0.28	-0.10 ± 0.27 (1)		
3c	H	OMe	OMe	Et	4.51 ± 0.04	-0.99 ± 1.04 (0.1)		
3d	OMe	H	OMe	Et	4.22 ± 0.06	1.19 ± 0.15 (16)		
4a	F	F	Ph	Et	3.75 ± 0.10	0.63 ± 0.24 (4)		
4b	F	OMe	Ph	Et	5.32 ± 0.11	0.59 ± 0.12 (4)		
4c	H	OMe	Ph	Et	4.08 ± 0.07	0.69 ± 0.20 (5)		
4d	OMe	H	Ph	Et	5.16 ± 0.15	0.70 ± 0.14 (5)		
5a	F	F	OMe	H	4.96 ± 0.13	2.62 ± 0.10(420)	2.18 ± 0.06 (150)	2.31 ± 0.28 (205)
5b	F	OMe	OMe	H	4.86 ± 0.03	1.31 ± 0.09 (20)		
5c	H	OMe	OMe	H	4.75 ± 0.05	1.68 ± 0.10 (48)		
5d	OMe	H	OMe	H	4.62 ± 0.12	2.20 ± 0.14 (160)	1.75 ± 0.17 (55)	
6a	F	F	Ph	H	5.36 ± 0.10	3.16 ± 0.13 (1450)	2.37 ± 0.20 (240)	2.87 ± 0.24 (740)
6b	F	OMe	Ph	H	5.84 ± 0.04	0.87 ± 0.12 (7)		
6c	H	OMe	Ph	H	5.71 ± 0.05	0.98 ± 0.11 (10)		
6d	OMe	H	Ph	H	5.67 ± 0.10	1.70 ± 0.10 (50)	1.92 ± 0.10 (85)	
7	OH	F	Ph	H	5.55 ± 0.17	2.41 ± 0.26 (257)		

Table 2: Binding and functional parameters for analogues of 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing amide or acid isostere groups ^a



	X	pK_B	$\text{Log} \alpha$ (α)	$\text{Log} \tau_B$ (τ_B)	$\text{Log} \beta$ ($\alpha\beta$)
11	CONH ₂	5.17 ± 0.12	1.51 ± 0.12 (32)		
10a	CONHCH ₃	4.92 ± 0.12	0.28 ± 0.10 (2)		
8a	CONHEt	5.78 ± 0.18	0.17 ± 0.10 (1.5)		
8b	CON(CH ₃) ₂	4.48 ± 0.19	0.85 ± 0.15 (7)		
8c		4.80 ± 0.37	-0.01 ± 0.16 (1.0)		
8d		4.63 ± 0.21	1.75 ± 0.20 (56)	1.25 ± 0.20 (18)	
8e		5.07 ± 0.15	1.45 ± 0.16 (28)		
8f		4.99 ± 0.07	2.22 ± 0.10 (170)	2.36 ± 0.06 (230)	2.92 ± 0.06 (840)
10b		4.65 ± 0.17	0.96 ± 0.12 (9)		
8g		4.97 ± 0.20	0.29 ± 0.13 (2)		
8h		4.71 ± 0.24	1.26 ± 0.21 (18)		
12	CN	4.66 ± 0.20	0.74 ± 0.17 (6)		
13		4.97 ± 0.18	1.89 ± 0.17 (78)	0.99 ± 0.07 (10)	
14		4.35 ± 0.07	1.04 ± 0.57 (11)		
8i		4.80 ± 0.20	1.52 ± 0.17 (33)		
9		4.63 ± 0.06	1.47 ± 0.19 (30)		

Table 3: Binding and functional parameters for 5,8-difluoro-1-(substituted-benzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid analogues^a






	R ^{3A}	R ^{3B}	pK _B	Log _a (α)	Logτ _B (τ _B)	Logαβ (αβ)
16a	2-Ph	H	5.00 ± 0.04	1.87 ± 0.08 (74)	1.10 ± 0.23 (13)	
16b	3-Ph	H	5.55 ± 0.16	1.64 ± 0.15 (44)		
22	-		4.96 ± 0.03	2.29 ± 0.07 (195)	1.82 ± 0.14 (65)	2.35 ± 0.09 (225)

Table 4: Binding and functional parameters for 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives bearing *N*-aryl or *N*-(substituted piperidine-4-methyl) groups^a



	X	pK _B	Log α_{ACh}
26a		4.65 ± 0.21	0.52 ± 0.15 (3)
26b		4.73 ± 0.26	-0.07 ± 0.10 (1)
28		4.70 ± 0.10	0.45 ± 0.09 (3)
29		4.82 ± 0.12	0.17 ± 0.10 (1.5)
31		5.13 ± 0.05	-0.02 ± 0.22 (1)
32		4.66 ± 0.08	0.99 ± 0.27 (10)



Graphical Abstract
40x16mm (300 x 300 DPI)